

## Oral Presentations

### Thursday, September 09, 2004

Antiinfectives - new and known non-synthetic compounds  
Clinical studies and use of antibiotics  
Pharmacokinetics and tissue penetration of antiinfectives  
Antivirals - clinical studies  
Resistance to antiinfectives  
Mechanisms of pharmacological and biochemical action of antiinfectives  
Antiinfectives - new and known synthetic compounds  
Pharmacodynamics and experimental therapy of antiinfectives  
Pharmacokinetics and tissue penetration of antiinfectives  
Targeted delivery of antineoplastic agents  
Antineoplastic agents - new and known synthetic compounds  
Mechanism of tumor development and growth  
Antineoplastic agents - new and known non-synthetic compounds  
Antineoplastic agents - clinical studies  
Blood brain barrier  
Adverse events, interactions and toxicity of antiinfectives  
Clinical studies and use of antibiotics  
Role of cells and their staining by dyes  
Clinical studies and use of antibiotics  
Antiinfectives - new and known synthetic compounds

### Friday, September 10, 2004

Mechanisms of pharmacological and biochemical action of antiinfectives  
Clinical studies and use of antibiotics  
Pharmacokinetics and tissue penetration of antiinfectives  
Antiinfectives - new and known synthetic compounds  
Antineoplastic agents - new and known synthetic compounds  
Antivirals & Antifungals - clinical studies  
Pharmacodynamics and experimental therapy of antiinfectives  
Pharmacokinetics and tissue penetration of antiinfectives  
Diagnostic tests in cancer / adverse events of cancer treatment & Adverse events of antineoplastic compounds  
Antiinfectives - new and known non-synthetic compounds  
Mechanism of tumor development and growth  
In vitro action of antimalarials  
Mechanisms of pharmacological importance  
Targeted delivery of antineoplastic agents  
Analytical techniques  
Role of cells and their staining by dyes  
Antineoplastic agents - new and known synthetic compounds  
Targeted delivery of antineoplastic agents  
Antimalarial compounds - clinical studies  
Adverse events, interactions and toxicity of antiinfectives  
Antineoplastic agents - new and known non-synthetic compounds & Antineoplastic agents - clinical studies  
Clinical studies and use of antibiotics  
Clinical studies and use of antibiotics

## **Saturday, September 11, 2004**

Microbiology & Resistance to antiinfectives

Antiviral agents

Mechanisms of pharmacological importance

Clinical studies and use of antibiotics

About mechanisms and Magic Bullets

Blood brain barrier

Mechanisms of action of antineoplastic agents including resistance

Agents involving the immune system

Design of drug delivery & Vaccination

## Oral Presentations

Thursday, September 09, 2004

**Category: Antiinfectives - new and known non-synthetic compounds**

**07:30 - 09:15 AM Room assignment will be printed in the final program**

- 353 Chemical Approaches for Improving ADME Properties of Lipoglycopeptide Antibiotics.  
**MU Y**, LINSELL M, LEADBETTER M, FATHEREE P, NODWELL M, TRAPP S, LAM B, PACE J, SHAW JP, JUDICE K  
Theravance Inc. South San Francisco, USA.
- 400 Therapeutic and Biotechnological Applications of Ribosomally Synthesized Antimicrobial Peptides.  
**PAPAGIANNI M**  
Department of Hygiene and Technology of Food of Animal Origin, School of Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- 548 Antimicrobial Activity of Chitosan including practical application.  
**Seichi Tokura**, Tetsuaki Tsuchido, Kaoru Negoro\* and Hiroshi Tamura  
Faculty of Engineering and HRC, Kansai University, Suita, Osaka, Japan  
\*Negoro Sanngyo Co. Ltd. Kishiwada, Osaka, Japan.
- 593 Medicinal Plants of Southeast Asia: A Source for New Antibiotics?  
**Christophe Wiart**  
Department of Pharmacy, Faculty of Medicine, University of Malaya, Malaysia.
- 139 Why has there been so little success in finding new high activity antimicrobial compounds from plants?  
**ELOFF JN**  
Programme for Phytomedicine, University of Pretoria, South Africa.
- 119 CAY-1, a Plant-produced Saponin Active against Phytopathogenic and Medical Pathogenic Fungi.  
**A. DE LUCCA**<sup>1</sup>, S. BOUE<sup>1</sup>, J. BLAND<sup>1</sup>, L. WARTELLE<sup>1</sup>, C. SELITRENNIKOFF<sup>2</sup>, S. RENAULT<sup>2</sup>, M. CUSHION<sup>3</sup>, T. CLEVELAND<sup>1</sup>, and T. WALSH<sup>4</sup>.  
<sup>1</sup>Southern Regional Research Center, USDA, New Orleans, LA USA; <sup>2</sup>Mycologics, Inc, Aurora, CO USA; <sup>3</sup>Univ. of Cincinnati College of Medicine, Cincinnati, OH USA; <sup>4</sup>National Cancer Institute, National Institutes of Health, Bethesda, MD USA.
- 562 *Kola acuminata* proanthocyanidins: a class of potent anti-trypanosomal drugs effective against the infective form of *Trypanosoma brucei*.  
**URADE Y**<sup>1</sup>, Kubata BK<sup>1,2,\*</sup>, Murakami N<sup>3</sup>, Merkel P<sup>4</sup>, Kabututu Z<sup>1,3</sup> Martin SK<sup>2</sup>, Duszenko M<sup>4</sup>  
<sup>1</sup>Osaka Bioscience Institute, Osaka, Japan;  
<sup>2</sup>US Army Medical Research Unit-Kenya, Nairobi, Kenya;  
<sup>3</sup>Osaka University, Osaka, Japan;  
<sup>4</sup>Universität Tübingen, Tübingen, Germany.

**Category: Clinical studies and use of antibiotics**

**07:30 - 09:15 AM Room assignment will be printed in the final program**

- 230 Abnormal acquisition of intestinal flora in surgical neonates and the efficacy of synbiotic therapy for pediatric surgical patients with intestinal or respiratory failure.  
**KANAMORI Y**<sup>1</sup>, HASHIZUME K<sup>1</sup>, SUGIYAMA M<sup>1</sup>, TOMONAGA T<sup>1</sup>, YUKI N<sup>2</sup>, TAKAHASHI T<sup>2</sup>, MOROTOMI M<sup>2</sup>.  
1)Department of Pediatric Surgery, The University of Tokyo Hospital, Tokyo JAPAN  
2)Yakult Central Institute for Microbiological Research, Tokyo JAPAN.
- 260 Outpatient Management of Low Risk Pediatric Oncology Patients with Fever and Neutropenia. How Do We Move from Clinical Trials to Clinical Practice?  
**KLAASSEN RJ**  
Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
- 483 The safety and efficacy of thalidomide in childhood tuberculous meningitis.  
**SCHOEMAN JF**<sup>1</sup>, SPRINGER P<sup>1</sup>, JANSE VAN RENSBURG A<sup>1</sup>, SWANEVELDER S<sup>2</sup>, HANEKOM W<sup>3</sup>, HASLETT P<sup>4</sup>, KAPLAN G<sup>5</sup>  
<sup>1</sup>Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital; <sup>2</sup>Biostatistics Unit, Medical Research Council; , Cape Town, South Africa  
<sup>3</sup>Department of Pediatrics, University of Miami, Miami, Florida, <sup>4</sup>Department of Microbiology and Immunology, University of Miami, Miami, Florida, and <sup>5</sup>Public Health Research Institute, International Center for Public Health, Newark, NJ, USA.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 035 Day-Care Based Management of Severe Pneumonia in Children with Injection Ceftriaxone.  
**ASHRAF H<sup>1</sup>**, ALAM NH<sup>1</sup>, MAHMUD R<sup>2</sup>, JAHAN SA<sup>1</sup>, HAQUE F<sup>3</sup>, GYR K<sup>4</sup> <sup>1</sup>ICDDR,B  
Centre for Health and Population Research, Dhaka, Bangladesh; <sup>2</sup>Radda MCH-FP Centre,  
Dhaka, Bangladesh, <sup>3</sup>Institute of Child Health & Shishu Hospital, Dhaka, Bangladesh,  
<sup>4</sup>University of Basel, Switzerland.
- 355 Updates on Antibiotic prophylaxis in Surgical Patients.  
**Nader D. Nader**  
FCCP
- 453 New Applications of Co-trimoxazole Therapy (Review).  
**ROZIN A**, MILITIANU D, EDOUTE Y  
Rambam Medical Center and B. Rappaport Faculty of Medicine, Israel-Technion Institute of  
Technology, Haifa, Israel.
- 267 IgY (Immunglobuline from egg-Yolk) - a tool to fight the emerging problem of antibiotic  
resistance.  
**KOLLBERG H<sup>1</sup>**, LARSSON A<sup>2</sup>, CARLANDER D<sup>2</sup>.  
<sup>1</sup>CF Center, University Children's Hospital, Uppsala, Sweden, <sup>2</sup>Dep. Med sciences, University  
Hospital, Uppsala, Sweden.

**Category: Pharmacokinetics and tissue penetration of antiinfectives**

**07:30 - 09:15 AM Room assignment will be printed in the final program**

- 521 Barriers to Magic Bullets; The Permeability of Mucosal Tissue to Therapeutic Agents.  
**SQUIER CA**, KREMER M, WERTZ PW  
Dows Institute for Dental Research, University of Iowa, Iowa City, Iowa, USA.
- 440 Tissue Penetration and Behaviour of Antibiotics in Acute Pancreatitis.  
**MAS MR**, TASCI I, ISIK AT  
Gulhane Medical Faculty, Ankara, Turkey.
- 508 Excretion and Resorption by the Skin.  
**SIMON GA**  
Israel Institute for Biological Research, Ness Ziona, Israel.
- 168 Cefotaxime and Ceftriaxone Cerebrospinal Fluid Levels During Treatment of Bacterial  
Meningitis in Children.  
**PN GOLDWATER**  
Microbiology & Infectious Diseases Department, The Women's & Children's Hospital, North  
Adelaide, South Australia, Australia.
- 078 Estimation of Amikacin Pharmacokinetic Parameters for South African Children.  
**BOTHA JH**, FORSYTH NB  
Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
- 253 Designing Antibiotics Dosage Regimens in Neonates Based on Population  
Pharmacokinetics (PPK): Comparative Study of Arbekacin (ABK), Vancomycin (VCM) and  
Panipenem (PAPM).  
**KIMURA T<sup>1</sup>**, YAGO K<sup>1</sup>, SUNAKAWA K<sup>1</sup>  
<sup>1</sup>Kitasato University Hospital, Kanagawa, Japan.
- 452 Antiinfective drug monitoring: time for change ?  
**ROUVEIX B**.  
Service de Pharmacologie Clinique, Hôpital Cochin–St Vincent de Paul, Paris, France.

**Category: Antivirals - clinical studies**

**08:00 - 09:00 AM Room assignment will be printed in the final program**

- 229 Adverse Effects on Brain Function caused by IFN- $\alpha$  –Evaluation from Quantitative-  
Electroencephalograms (q-EEG) in IFN-  $\alpha$  Treated Hepatitis C Patients-  
**KAMEI S<sup>1</sup>**, MATSUURA M<sup>2</sup>, TANAKA N<sup>3</sup>, ARAKAWA Y<sup>3</sup>, KOJIMA T<sup>2</sup>, MATSUKAWA Y<sup>4</sup>,  
MIZUTANI T<sup>1</sup>, MORIYAMA M<sup>3</sup>, HIRAYANAGI K<sup>5</sup>  
Divisions of <sup>1</sup>Neurology, <sup>3</sup>Gastroenterology and Hepatology, and <sup>4</sup>Hematology and  
Rheumatology, Department of Medicine, and Departments of <sup>2</sup>Neuropsychiatry, and  
<sup>5</sup>Hygiene and Public Health, Nihon University School of Medicine, Tokyo, Japan.
- 471 Selective Myeloid Cell Purging as a Novel Adjunct to Interferon- $\alpha$ +Ribavirin Combination  
Therapy in Patients with High Plasma HCV Viraemia Resistant to Interferon: An Enhanced  
Immune Function Against HVC.  
**Saniabadi AR<sup>1</sup>**, Sawada K<sup>2</sup>, Hirata I<sup>1</sup>, Fukunaga K.<sup>3</sup>  
<sup>1</sup>Japan Immunoresearch Laboratories; <sup>2</sup>Fujimoto Hospital Medicine; <sup>3</sup>Hyogo College of  
Medicine, Japan.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 054 Treatment of HIV-1/AIDS Patients with CpG ODN May Stop the Pandemic.  
**BECKER Y**  
The Hebrew University of Jerusalem, Jerusalem, Israel.
- 378 Toxoplasmosis In HIV/AIDS Patients: A Current Situation.  
**NISSAPATORN VEERANOOT<sup>1</sup>**, LEE CHRISTOPHER<sup>2</sup>, QUEK KIA FATT<sup>3</sup>, LEONG CHEE LOON<sup>2</sup>, MAHMUD ROHELA<sup>1</sup>, ABDULLAH KHAIRUL ANUAR<sup>1</sup>  
<sup>1</sup>Department of Parasitology, <sup>3</sup>Department of Social and Preventive Medicine, University of Malaya Medical Centre, Kuala Lumpur, Malaysia. <sup>2</sup>Department of Medicine, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.

**Category :**                    **Resistance to antiinfectives**

**08:15 - 10:15 AM**           **Room assignment will be printed in the final program**

- 584 *In vitro* Antimicrobial Resistance in Bacteria Exposed to Residue Level Exposures of Antimicrobial Drugs, Pesticides and Veterinary Drugs.  
D KLEINER, SE KATZ, **PL WARD**  
Cook College, NJAES, Rutgers, the State University of New Jersey, New Brunswick, NJ, USA.
- 144 Strategies for Containment of Antibiotic Resistance in Developing Countries – Lessons from South Africa.  
**ESSACK, SY**  
University of KwaZulu-Natal, Durban, South Africa.
- 095 Yearwise (1989-2003) prevalence of drug resistance to various drugs among gram negative bacilli isolated from hospitalized cases in Central India.  
**Chitnis S**, Chitnis V, Hemwani N and Chitnis DS.
- 162 Isolation of Multidrug-Resistant *Stenotrophomonas maltophilia* from a Marine Cultured Fish.  
**FURUSHITA M<sup>1,2</sup>**, MAEDA T<sup>1</sup>, OKAMOTO A<sup>2</sup>, OHTA M<sup>2</sup>, SHIBA T<sup>1</sup>  
<sup>1</sup>Department of Food Science and Technology, National Fisheries University, Shimonoseki, Japan; <sup>2</sup>Graduate School of Medicine, Nagoya University, Nagoya, Japan.
- 237 Antibiogram of Bacteria from Slaughter Animals on the Data of Resistance Monitoring System in 2003.  
**J-KASZANYITZKY É, JÁNOSI, S**  
Central Veterinary Institute, Budapest, Hungary.
- 122 Antiparasitic Drug Resistance: Lessons from Ivermectin and a Model Nematode.  
**DENT JA<sup>1</sup>**  
<sup>1</sup>McGill University, Montreal, QC, Canada.
- 281 Evolution Of Drug Resistance In A University Hospital In Singapore (NUH).  
**KUMARASINGHE G, JAYASURYA A, LIM SM, CHOW C.**  
National University Hospital, Singapore.
- 338 Antimicrobial Usage Data in Humans and Food Animals from 1995 to 2001 in Kenya.  
**MITEMA, ES<sup>1</sup>**, KIKUVI, G<sup>1</sup>  
<sup>1</sup>Pharmacology and Toxicology Laboratory, Faculty of Veterinary Medicine, University of Nairobi, Nairobi, Kenya.

**Category:**                    **Mechanisms of pharmacological and biochemical action of antiinfectives**

**09:30 - 11:45 AM**           **Room assignment will be printed in the final program**

- 563 Anti-Inflammatory Activity of Macrolides and Fluoroquinolones on Human Endothelial Cells.  
**URIARTE SM<sup>1</sup>**, MOLESTINA RE<sup>1</sup>, MILLER RD<sup>1</sup>, RAMIREZ JA<sup>1</sup>, SUMMERSGILL JT<sup>1</sup>.  
<sup>1</sup>University of Louisville School of Medicine, Louisville, KY, USA.
- 358 Crystal Structure Based Assembly of the MexAB-OprM Multidrug Efflux Pump in *Pseudomonas aeruginosa*.  
**NAKAE, T<sup>1</sup>**, AKAMA, H<sup>1</sup>, MATSUURA, T<sup>2</sup>, TSUKIHARA, T<sup>2</sup>, and NAKAGAWA, A<sup>2</sup>  
<sup>1</sup>Tokai University School of Medicine, Isehara, Japan; <sup>2</sup>Osaka University Institute for Protein Research, Suita, Japan.
- 084 Polymyxin B-Mediated Selective Lipid Exchange: Implications in Antibacterial Action.  
**CAJAL Y<sup>1</sup>**  
<sup>1</sup>Universitat de Barcelona, Barcelona, Spain.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 324 Monosaccharide Lipid A Analogues; Their Potencial as Magic Bullets to Enhance Host Innate Immunity against Microbial Infections.  
**MATSUURA M**  
Department of Infection and Immunity, Jichi Medical School, Tochigi, Japan.
- 333 The effect of combined antimicrobial treatment on prokaryotic cells and on certain groups of eukaryotic cells.  
**MILANKOVITS M.**  
Hungarian National Institute of Genitourinary Medicine Foundation, Budapest, Hungary.
- 406 Mechanisms of Induction and Regulation of Gut Mucosal Immune Stimulation by Non-Pathogenic Bacteria.  
Maldonado Galdeano C.<sup>1,2</sup>, Dogi C.<sup>1</sup>, Bibas Bonet M.E.<sup>1,2</sup>, Chaves S<sup>1</sup>. And **Perdigón G.**<sup>1,2</sup>  
<sup>1</sup>CERELA, Chacabuco, Tucumán, Argentina.  
<sup>2</sup>Cátedra de Inmunología, FBQyF, Universidad Nacional de Tucumán, Argentina.
- 409 The Interface of Triosephosphate Isomerase of *Trypanosoma cruzi* as a Target for the Development of New Drugs for Chagas' Disease.  
**PEREZ-MONTFORT R<sup>1</sup>**, GOMEZ-PUYOU A<sup>1</sup>  
<sup>1</sup>Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, México DF, México.
- 514 Forcing Nanoscopic Infectious Agents to Incorporate Antiinfectives by Exposure to Moderate Laser Light Intensities – Solutions Inspired by Nature.  
**SOMMER, AP**  
Central Institute of Biomedical Engineering, University of Ulm, Ulm, Germany.
- 542 A New Type of Magic Bullet? Therapeutic Agents that Modify Rather than Kill the Pathogen.  
**TAYLOR PW<sup>1</sup>**, MUSHTAQ N<sup>1</sup>, LUZIO JP<sup>2</sup>  
<sup>1</sup>School of Pharmacy, London, United Kingdom; <sup>2</sup>Cambridge Institute for Medical Research, Cambridge, United Kingdom.

**Category: Antiinfectives - new and known synthetic compounds**

**09:30 - 11:30 AM**

**Room assignment will be printed in the final program**

- 394 Structural Modification of Dibenzosuberanylpiperazine and Diphenylacetyl- piperazine Derivatives Mainly for Efficient Reduction of Chloroquine Resistance in *Plasmodium chabaudi*.  
**OSA Y<sup>1</sup>**, KOBAYASHI S<sup>2</sup>, SATO Y<sup>1</sup>, SUZUKI Y<sup>2</sup>, TAKINO K<sup>1</sup>, HIKIMA Y<sup>1</sup>, TAKEUCHI T<sup>2</sup>, MIYATA Y<sup>3</sup>, SAKAGUCHI M<sup>3</sup>, TAKAYANAGI H<sup>1</sup>, NAGASE H<sup>1</sup>  
<sup>1</sup>Kitasato University, Tokyo, Japan, <sup>2</sup> Keio University, Tokyo, Japan, <sup>3</sup> Pola Chemical Industries, Inc., Yokohama, Japan.
- 067 New pyrrole derivatives of BM 212: a new class of antimycobacterial agents.  
**Biava M<sup>1\*</sup>**, Porretta<sup>1</sup> GC, Pompei R<sup>2</sup>, Laconi S<sup>2</sup>, Manetti F<sup>3</sup>, Botta M<sup>3</sup>  
<sup>1</sup>Dipartimento di Studi di Chimica e Tecnologia delle Sostanze Biologicamente Attive, Università "La Sapienza", Rome  
<sup>2</sup>Cattedra di Microbiologia Applicata, Facoltà di Scienze Matematiche Fisiche Naturali, Università degli Studi di Cagliari, Cagliari, Italy; <sup>3</sup>Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via Aldo Moro snc.
- 200 Development of Hexadecyloxypropyl-cidofovir: An Oral Drug for the Prevention and Treatment of Smallpox.  
**HOSTETLER, KY**  
Department of Medicine, University of California, San Diego and the San Diego VA Healthcare System, San Diego, California, USA.
- 505 Improving and Assessing the Effectiveness of Antiinfective Drugs by Molecular Design and Theranostic Devices.  
**SIA SK**  
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA (USA).
- 071 Evidence for in vitro trypanocidal activity of methylene blue, but in vivo failure.  
**Caroline Boda**, Bertin Enanga, Bertrand Courtioux, Christian Breton, Bernard Bouteille  
UPRES-EA 3174 Neuroparasitologie et neuroépidémiologie tropicale  
Faculty of medicine, Limoges Cedex (France).
- 303 Antileishmanial Drug Discovery & Development: Experiences With Drug Candidate PX-6518.  
**MAES L<sup>1</sup>**, COS P<sup>1</sup>, VANDEN BERGHE D<sup>1</sup>, VAN PUYVELDE L<sup>2</sup>  
<sup>1</sup>Laboratory for Microbiology, Parasitology & Hygiene, University Antwerp, Belgium;  
<sup>2</sup>Vietnamese Academy of Science and Technology, Hanoi, Vietnam.
- 092 New "Magic Bullets" and Hypermutability Leading to Cytotoxic Resistance Emergence in *Escherichia coli*.  
**CHEREPENKO YI<sup>1</sup>**, POTYAHAYLO AL<sup>1</sup>, HOVORUN DM<sup>1</sup>  
<sup>1</sup>Institute of Molecular Biology and Genetics, Kyiv, Ukraine.

- 500 Prolonging the action of protein and peptide drugs by a novel approach of reversible PEGylation.  
HAIM TSubERY<sup>1,2</sup>, MARINA MIRONCHIK<sup>1</sup>, MATI FRIDKIN<sup>2</sup> AND YORAM SHECHTER<sup>1</sup>  
Departments of <sup>1</sup>Biological Chemistry and <sup>2</sup>Organic Chemistry  
The Weizmann Institute of Science, Rehovot, Israel.

**Category: Pharmacodynamics and experimental therapy of antiinfectives**

**10:00 - 11:45 AM Room assignment will be printed in the final program**

- 382 Monte Carlo Simulation versus *S.pneumoniae* of Levofloxacin 500mg, 750mg and 1000mg Once Daily Compared to Gatifloxacin 200mg and 400mg Once Daily Administered to Hospitalized Patients with Community Acquired Pneumonia (CAP): Dose and Age Stratification Study.  
**NOREDDIN AM**<sup>1,2</sup>, MARRAS TK<sup>4</sup>, CHAN CK<sup>4</sup>, HOBAN DJ<sup>2,3</sup> and Zhanel GG<sup>2,3</sup>  
<sup>1</sup>College of Pharmacy, University of Minnesota, Duluth, MN, USA; <sup>2</sup>Faculty of Medicine, University of Manitoba; <sup>3</sup>Health Sciences Centre, Winnipeg, MB; <sup>4</sup>University of Toronto, Toronto, ON, Canada.
- 232 The impact of dosing frequency on patient compliance with antiinfectives – is there an evidence that once-daily dosage is a real solution?  
**KARDAS P**<sup>1</sup>  
<sup>1</sup>Medical University of Lodz, Lodz, Poland.
- 632 Mutant Selection Window.  
**DRLICA K**, ZHAO X, LI X, WANG J, URBAN C, PERLIN D  
Public Health Research Institute, Newark, NJ, USA
- 635 APC Anti-infective Action Is Augmented By APC Activation Of Protein C.  
**HASSOUNA HI**, Penner J  
Department of Medicine Michigan State University, Clinical Center East Lansing, MI, USA
- 451 Subcellular Drug Transport and the Effectiveness of Anti-infectives.  
CHEN V<sup>1</sup>, SHEDDEN K<sup>1</sup>, ELLIOTT A<sup>1</sup> AND **ROSANIA GR**<sup>1</sup>  
<sup>1</sup>University of Michigan, Ann Arbor.
- 388 Invasive group A *Streptococcus* infections followed by intranasal superinfection with influenza A virus in mice: Cure and prevention of lethal synergism.  
**OKAMOTO S**<sup>1,3</sup>, HAMADA S<sup>1</sup>, KAWABATA S<sup>1,2</sup>  
<sup>1</sup>Osaka University Graduate School of Dentistry, Suita-Osaka, Japan; <sup>2</sup>Japan Science and Technology Agency, Kawaguchi-Saitama, Japan; <sup>3</sup>Fukuoka Dental College, Fukuoka, Japan.
- 202 Treatment of *Toxocara canis* (Nematoda) Infection in Mice with Albendazole Incorporated into Liposome Carriers and Immunomodulator  $\beta$ -glucan.  
**HRČKOVA G**, VELEBNY S, TOMAŠOVIČOVA O, ČORBA J  
Parasitological Institute, Košice, Slovak Republic.

**Category: Pharmacokinetics and tissue penetration of antiinfectives**

**10:30 - 11:45 AM Room assignment will be printed in the final program**

- 105 Prediction of *in vivo* Human Pharmacokinetics from Nonclinical Data.  
**COOK CC**  
Baxter Healthcare, Round Lake IL, U.S.A.
- 408 EFFECT OF PARASITISM ON THE PLASMA DISPOSITION AND BIOAVAILABILITY OF DORAMECTIN IN LAMBS.  
**R. Pérez**<sup>1</sup>, C. Palma<sup>1</sup>, I. Cabezas<sup>1</sup>, L. Rubilar<sup>1</sup> and M. Arboix<sup>2</sup>.  
1: Facultad Medicina Veterinaria, Universidad de Concepción. Chillán - Chile. 2. Laboratorio Farmacología. Facultad Veterinaria. Universidad Autónoma de Barcelona, Bellaterra, Barcelona – España.
- 481 The Relative Bioavailability of Three Newly Developed Albendazole Formulations: a Randomized Cross-Over Study in Healthy Volunteers.  
IM RIGTER<sup>1</sup>, **HG SCHIPPER**<sup>1</sup>, RP KOOPMANS<sup>1</sup>, HJM VAN KAN<sup>1</sup>, HG FRIJLINK<sup>2</sup>, PA KAGER<sup>1</sup>, HJ GUCHELAAR<sup>1</sup>  
Academic Medical Center<sup>1</sup>, University of Amsterdam, The Netherlands. University of Groningen<sup>2</sup>, The Netherlands.
- 023 Antibiotic dosing in hepatic failure.  
**AMARAPURKAR DN**  
Department of Gastroenterology & Hepatology Bombay Hospital & Medical Research Centre, Mumbai India.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 299 A New Method to Predict Glomerular Filtration Rate and Adjust Drug Dose to Renal Function.  
**DONADIO C**, CONSANI C, ARDINI M, BERNABINI G, CAPRIO F, GRASSI G, LUCCHESI A  
Department of Internal Medicine – Nephrology, University of Pisa, Pisa, Italy.

**Category: Targeted delivery of antineoplastic agents**

**11:45 AM - 02:00 PM Room assignment will be printed in the final program**

- 294 Radiolanthanides for Pretarget and Conventional Radioimmunotherapy of Cancer: "Magic Bullets" versus "Smart Bombs".  
**LEWIS MR**<sup>1,2,3</sup>, MOHSIN H<sup>4</sup>, SIVAGURU G<sup>1</sup>, JIA F<sup>1</sup>, BRYAN JN<sup>1</sup>, SHELTON TD<sup>5</sup>, HOFFMAN TJ<sup>5</sup>, CUTLER CS<sup>5</sup>, KETRING AR<sup>6</sup>, ATHEY PS<sup>7</sup>, SIMÓN J<sup>7</sup>, FRANK RK<sup>7</sup>, AXWORTHY DB<sup>8</sup>, JURISSON SS<sup>4,6</sup>  
<sup>1</sup>Veterinary Medicine and Surgery, <sup>2</sup>Radiology, <sup>3</sup>Nuclear Science and Engineering Institute, <sup>4</sup>Chemistry, <sup>5</sup>Internal Medicine, <sup>6</sup>Research Reactor Center, University of Missouri, Columbia, MO; <sup>7</sup>The DOW Chemical Company, Freeport, TX; <sup>8</sup>Aletheon Pharmaceuticals, Seattle, WA, USA.
- 439 Tumor-targeting of Antineoplastics using Nano-sized Drug Carriers and Focused Ultrasound.  
**Rapoport NY**  
University of Utah, Salt Lake City, Utah, USA.
- 014 Targeted Block Copolymer Drug Formulations for Oncology. Pre-Clinical and Clinical Experience.  
**ALAKHOV V**  
Supratek Pharma Inc., Dorval, Quebec, Canada.
- 292  $\alpha_v\beta_3$ -Integrin Targeted Camptothecin Conjugates.  
**LERCHEN HG**<sup>1</sup>, BAUMGARTEN J<sup>1</sup>, LYNCH M<sup>2</sup>, ALBERS M<sup>1</sup>, BRUEGGEMEIER U<sup>1</sup>, BURGER AM<sup>3</sup>, FIEBIG HH<sup>3</sup>.  
<sup>1</sup>Bayer HealthCare AG, Wuppertal, Germany; <sup>2</sup>Bayer Corp. West Haven, USA, <sup>3</sup>Oncotest GmbH, Freiburg, Germany.
- 301 Polymer therapeutics and cancer targeting principle, EPR-effect, ---- towards the magic bullets.  
**MAEDA H**  
Sojo University; Kumamoto University, and BioDynamics Research Laboratory, Kumamoto, Japan.
- 336 Extracellular and Intracellular Molecular Targeting of Drug Delivery System to Cancer Cells.  
**MINKO T**  
Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
- 370 "Targeted" Molecular Chemotherapy for Brain Tumors – Searching for the "Magic Bullet".  
**NEWTON HB**  
Division of Neuro-Oncology and Dardinger Neuro-Oncology Center, Ohio State University Medical Center and James Cancer Hospital & Solove Research Institute, Columbus, Ohio, USA.
- 098 Antisense DNAs: Targeted Genetic Medicine to Treat Cancer.  
**CHO-CHUNG YS**  
Cellular Biochemistry Section, Basic Research Laboratory, National Cancer Institute, NIH, Bethesda, MD, U.S.A.
- 051 Novel Oligonucleotides Inhibiting STAT3: Use in Hormone-Refractory Prostate Cancer.  
**BARTON BE**, MURPHY TF, SHU P, HUANG HF, BARTON A  
UMDNJ-New Jersey Medical School, Newark, NJ, USA.

**Category: Antineoplastic agents - new and known synthetic compounds**

**12:00 - 01:30 PM Room assignment will be printed in the final program**

- 104 Metal Based Anti-Cancer Drugs with Anti-Leukemic Thiobases and COX-inhibitors as Ligands.  
**CINI R**  
Department of Chemical and Biosystem Sciences and Technologies, University of Siena, Siena, Italy.



World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 344 An Innovative Approach for DNA Inactivation Using Combination of Phenothiazine Dyes, Rhodium Complex, and Visible Light.  
**Taj Mohammad**  
Purdue University, Department of Chemistry, and Department of Forestry and Natural Resources, IN, U. S. A.
- 519 Antineoplastic polyanions in cancer strategy.  
**SORIMACHI K**  
Dokkyo University School of Medicine, Mibu, Japan.
- 100 Enhanced Antineoplastic Efficacy *in vivo* of Lactone-Stabilized Camptothecins by Chemical Modification or Liposomal Delivery.  
**CHOW DSL<sup>1</sup>, LI X<sup>1</sup>, GONG L<sup>1</sup>, WOLFE MD<sup>1</sup>, GIOVANELLA BC<sup>2</sup>**  
<sup>1</sup>College of Pharmacy, University of Houston, Houston, TX, USA; <sup>2</sup>Stehlin Foundation for Cancer Research, Houston, TX, USA.
- 477 Destruction of Human Breast Cancer Cells by Tumor-targeted *Salmonella typhimurium*.  
**SCHATTEN H<sup>1</sup>, FEA, A<sup>1</sup> and EISENSTARK, A<sup>1</sup>**  
<sup>1</sup>Dept. of Veterinary Pathobiology, Univ. of Missouri-Columbia, Columbia, MO, USA, <sup>2</sup>Cancer Research Center, Columbia, MO, USA.
- 504 Development of Tumor-Activated Prodrugs of Cytotoxics (TAC).  
**SHIMMA N<sup>1</sup>, ISHITSUKA H<sup>2</sup>, OKABE H<sup>1</sup>, UMEDA I<sup>1</sup>, Hattori K<sup>1</sup>, Miwa M<sup>1</sup>**  
<sup>1</sup>Chugai Pharm. Co. Ltd., Kamakura, Japan; <sup>2</sup>Roche Diagnostics, Tokyo, Japan.

**Category: Mechanism of tumor development and growth**

**12:00 - 13:30 PM**

**Room assignment will be printed in the final program**

- 397 A Mathematical Model for Capillary Formation and Development in Tumor Angiogenesis.  
**PAMUK S**  
University of Kocaeli, Kocaeli, Turkey.
- 319 Intracellular Targeting of <sup>10</sup>B compounds (<sup>10</sup>BSH) to Solid Tumors by Transferrin-Pegylated Liposomes (TF-PEG-LP), for Boron Neutron-Capture Therapy (BNCT).  
**Maruyama K<sup>1</sup>, Kasaoka S<sup>1</sup>, Takizawa T<sup>1</sup>, Suzuki R<sup>1</sup>, Utoguchi N<sup>1</sup>, Yanagie H<sup>2</sup>, Shinohara A<sup>3</sup>, Ono K<sup>4</sup>**  
<sup>1</sup>Teikyo University, Kanagawa, Japan; <sup>2</sup>University of Tokyo, Tokyo, Japan; <sup>3</sup>Juntendo University, Tokyo, Japan; <sup>4</sup>Kyoto University, Kyoto, Japan.
- 598 Mechanisms of Acute 5-Fluorouracil Chemotherapy-Induced Bone Growth Arrest in Young Rats.  
**CJ Xian, J Cool, BK Foster**  
Department of Orthopaedic Surgery, Women's and Children's Hospital, South Australia.
- 289 Detection of PDGFRB and ETV6 gene rearrangement in five cases of atypical chronic myeloid leukemia with 5q chromosome abnormalities.  
**LAZARIDOU A, MAVROUDI S, CHRISTAKIS JI**  
Cancer Hospital of Thessaloniki, Hematology Department, Greece.
- 480 Increasing tissue and cell penetration of therapeutic DNA by electrotransfer.  
**SCHERMAN D., BIGEY P, BLOQUEL C, TROLLET C**  
Laboratoire de Pharmacologie Chimique et Génétique, Faculté de Pharmacie Paris 5.
- 568 Inhibition of the RhoC GTPase-Mediated Inflammatory Breast Cancer Phenotype by Farnesyl Transferase Inhibitors.  
**GROH KE, RADUNSKY GS and VAN GOLEN KL**  
The University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

**Category: Antineoplastic agents - new and known non-synthetic compounds**

**12:45 - 03:15 PM**

**Room assignment will be printed in the final program**

- 485 Selenium in Cancer Prevention and Therapy.  
**G.N.Schrauzer**  
University of California, San Diego, USA.
- 218 Characterization of Vitamin C: K<sub>3</sub> Induced Autoschizis in Human Bladder Cancer Cell Lines.  
**Jamison JM<sup>1</sup>, Summers JL<sup>1</sup>, Gilloteaux J<sup>2</sup>, Buc-Calderon P<sup>3</sup>, Taper HS<sup>3</sup>**  
<sup>1</sup>Summa Health System/ NEOUCOM, Akron, Ohio, USA; <sup>2</sup>American University of the Caribbean, St. Maarten, Netherland Antilles, West Indies; <sup>3</sup>Université Catholique de Louvain, Brussels-Woluwe, Belgium.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 201 Molecular Mechanism of Apoptosis Induction by Polyphenolic Compounds: Targeting Reactive Oxygen Species (ROS) and Mitochondria.  
**HOU D-X**, Kubo M, Harazono K, Imamura I, Morishita A, Tong X, Uto T, Takeshita T, Fujii M.  
Faculty of Agriculture, Kagoshima University, Kagoshima, Japan.
- 547 VEGF and its intrinsic inhibitory protein in human cancer.  
**TOI M**<sup>1</sup>, BANDO H<sup>1</sup>, WEICH HA<sup>2</sup>  
<sup>1</sup>Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome, Tokyo, Japan  
<sup>2</sup>German Research Center for Biotechnology, Braunschweig, Germany.
- 027 Conjunction of Small Interfering RNAs and Tumor-Penetrating Peptides Could Provide Novel Antineoplastic Agents.  
**Aoki Y**<sup>1,2</sup>, Oguchi S<sup>1</sup>, Kumagai M<sup>1</sup>, Suzawa K<sup>1</sup>, Otsuki T<sup>2</sup>, Miyamoto T<sup>2</sup>, Hashizume K<sup>2</sup>, Nakajima K<sup>3</sup>  
<sup>1</sup>Department of Internal Medicine, Matsumoto National Hospital, Matsumoto, Japan;  
<sup>2</sup>Department of Aging Medicine and Geriatrics, Institute on Aging and Adaptation, Shinshu University Graduate School, Matsumoto, Japan; <sup>3</sup>Peptide Institute, Inc., Osaka, Japan.
- 385 Screening of Natural Compounds for Inhibitory Activity on Tumor Cell Migration and Metastasis.  
**OGASAWARA M**, MATSUBARA T, MATSUNAGA T, TAKAHASHI S, SUZUKI H  
Toyama Prefectural Institute for Pharmaceutical Research, Toyama, Japan.
- 024 Leptosins Isolated from Marine Microorganism *Leptoshaeria* sp. Inhibit DNA Topoisomerases and Induce Apoptosis in a Panel of Human Cancer Cell Lines.  
**Andoh T**<sup>1</sup>, Yanagihara M<sup>1</sup>, Takahashi-Sasaki, N<sup>1</sup>, Yamamoto S<sup>1</sup>, Numata A<sup>2</sup>, Yamori T<sup>3</sup>  
<sup>1</sup>Soka University Tokyo, <sup>2</sup>Osaka University of Pharmaceutical Sciences, Osaka,  
<sup>3</sup>Foundation for Cancer Research, Tokyo, Japan.
- 387 A Newly Identified Antineoplastic Molecule Derived from *Streptococcus pyogenes*: Involvement of Toll-Like Receptor (TLR) 4 Signaling.  
**OKAMOTO M**  
Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, Tokushima, Japan.
- 223 An antineoplastic compound from *Murdannia loriformis*.  
**JIRATCHARIYAKUL W**<sup>1</sup>, VONGSAKUL M<sup>2</sup>, SUNTHORNSUK L<sup>1</sup>, MOONGKARNDI P<sup>1</sup>, SOMANABANDHU A<sup>1</sup>, OKABE H<sup>3</sup>, FRAHM AW<sup>4</sup>  
<sup>1</sup>Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; <sup>2</sup>Faculty of Science, Mahidol University, Bangkok, Thailand; <sup>3</sup>Laboratory of Pharmacognosy and Plant Chemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan; <sup>4</sup>Dept. of Pharmaceutical Chemistry, Albert-Ludwigs-University, Freiburg, Germany.
- 093 Flying Bullets: Cytokine-like Antineoplastic Peptides from Insects.  
**CHERNYSH SI**<sup>1</sup>, PLESKACH VA<sup>2</sup>, TULIN DV<sup>1</sup>  
<sup>1</sup>St.Petersburg University, St.Petersburg, Russia; <sup>2</sup>Institute of Cytology, St.Petersburg, Russia.

**Category: Antineoplastic agents - clinical studies**

**02:00 - 04:35 PM Room assignment will be printed in the final program**

- Individual dose adaptation in cancer chemotherapy  
**Jaehde U.**  
Inst. of Pharmacy, Dept. Clinical Pharmacy, University of Bonn, Germany.
- 160 Tissue Concentrations of some Antineoplastic Drugs in Cancer Patients.  
**FURLANUT M**<sup>1</sup>, FRANCESCHI L<sup>1</sup>, GIORDA G<sup>2</sup>, DE MANZONI G<sup>3</sup>, PASINI F<sup>3</sup>, CARTEI G<sup>4</sup>, CAGOL PP<sup>5</sup>  
<sup>1</sup>DPMSC University of Udine, Italy; <sup>2</sup>CRO Aviano, Italy; <sup>3</sup>General Surgery, University of Verona, Italy; <sup>4</sup>Oncology Unit, General Hospital, Padua, Italy; <sup>5</sup>General Surgery, University of Udine, Italy.
- 191 Magic Bullets Against Non-Small Cell Lung Cancer (NSCLC) are Becoming A Reality – Targets are in Sight.  
**HIRSH V**<sup>1</sup>  
<sup>1</sup>Royal Victoria Hospital, McGill University, Montreal, Canada.
- 350 Clinical Features, Response to Treatment, and Survival in Small Cell Lung Cancer: Effect of Histological Variability.  
**MORAN EM**<sup>1,2</sup>, IYER PR<sup>1,2</sup>, KANESHIRO CA<sup>2</sup>  
<sup>1</sup>Department of Medicine, University of California, Irvine, Irvine, California; <sup>2</sup>Long Beach VA Healthcare System, Long Beach, California, USA.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 428 Antiangiogenic Drugs for Chemotherapy of Bladder Tumors.  
**POSSATI L**<sup>1</sup>, MARGIOTTA C<sup>1</sup>, ROCCHETTI R<sup>1</sup>, CALZA R<sup>1</sup>, TALEVI S<sup>1</sup>, CORALLINI A<sup>2</sup>  
<sup>1</sup>Institute of Microbiology and Biomedical Sciences, Polytechnic University of Marche, Ancona, Italy; <sup>2</sup>Department of Experimental and Diagnostic Medicine, Section of Microbiology, University of Ferrara, Italy.
- 450 Urinary Bladder Carcinogenesis after the Chernobyl Accident in Ukraine (Molecular Mechanisms).  
**ROMANENKO AM**<sup>1</sup>, VOZIANOV AF<sup>1</sup>, FUKUSHIMA S<sup>2</sup>  
<sup>1</sup>Institute of Urology, Kiev, Ukraine; <sup>2</sup>First Department of Pathology, Osaka City University Medical School, Osaka, Japan.
- 426 Sequential Chemotherapy in Advanced Colorectal Cancer: Results of Five Arms Study.  
**POPOV I**<sup>1</sup>, JELIC S<sup>1</sup>, KRIVOKAPIC Z<sup>2</sup>, MICEV M<sup>2</sup>, JEZDIC S<sup>1</sup>, ZDRAVKO Z<sup>1</sup>, KEZIC I<sup>1</sup>.  
<sup>1</sup>Institut of Oncology and Radiology, Belgrade, Serbia; <sup>2</sup>First University Surgery Clinic, Belgrade, Serbia.
- 606 A Novel Chemotherapeutic Strategy against Colorectal Cancer Manipulating Dual Cell Death by Five-fluorouracil (5-FU); High-Dose Shorter plus Low-Dose Metronomic Regimen.  
**Yoshikawa R**<sup>1,2</sup>, Yanagi H<sup>1</sup>, Noda M<sup>1</sup>, Hashimoto-Tamaoki T<sup>2,3</sup>, Kusunoki M<sup>4</sup>, and Yamamura T<sup>1,2</sup>.  
<sup>1</sup>2nd Dept of Surg, <sup>2</sup>Inst for Adv Med Sci, <sup>3</sup>Dept of Genet, Hyogo College of Medicine, Nishinomiya, Hyogo; <sup>4</sup>2nd Dept of Surg, Mie Univ, Tsu, Mie, JAPAN.
- 215 High-Dose Methotrexate With Leukovorin Rescue: Impact On The Management of Osteosarcoma.  
**JAFFE N**<sup>1</sup>  
<sup>1</sup>University of Texas M. D. Anderson Cancer Center, Division of Pediatrics, Houston, TX.
- 615 Latest Developments in Drug Treatment for Skin Cancers.  
**ZEITOUNI NC**  
Roswell Park Cancer Institute, Buffalo, New York, USA.

**Category:**

**Blood brain barrier**

**02:00 - 03:15 PM**

**Room assignment will be printed in the final program**

- 459 Amylin, the Regulation of Energy Homeostasis, and the Blood-Brain Barrier.  
**RUSHING PA**  
National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
- 543 Brain-to-Blood Efflux Transporters for Hydrophilic Endogenous Substrates at the Blood-Brain Barrier as a CNS detoxifying system.  
**TERASAKI T**<sup>1</sup>, OHTSUKI S<sup>2</sup>  
<sup>1</sup>New Industry Creation Hatchery Center (NICHe), and <sup>2</sup>Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan; <sup>3</sup>CREST and SORST, Japan Science and Technology Agency, Japan.
- 128 Passage of Vasoactive Intestinal Peptide (VIP) Across the Blood-Brain Barrier and Comparison with Respect to the Passage of VIP/PACAP/Secretin Family Members.  
**DOGRUKOL-AK D**<sup>1</sup>, BANKS WA<sup>2</sup>, TUNCEL N<sup>3</sup>, TORE F<sup>4</sup>, TUNCEL M<sup>1</sup>  
<sup>1</sup>Department of Analytical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey, <sup>2</sup>GRECC, Department of Internal Medicine, Division of Geriatrics, School of Medicine, Veterans Affairs Medical Center and Saint Louis University, St. Louis, MO, USA, <sup>3</sup>Department of Physiology, Faculty of Medicine, Osmangazi University, 26480 Eskisehir, Turkey, <sup>4</sup>Department of Physiology, Izzet Baysal Medical Faculty, Abant Izzet Baysal University, 14280 Bolu, Turkey.
- 468 Evidence of Pralidoxime Iodide (2-PAM) Penetration Across the Blood-Brain Barrier.  
**Sakurada K**<sup>1</sup>, Matsubara K<sup>2</sup>, Ohta H<sup>1</sup>, Ohmori T<sup>1</sup>, Takatori T<sup>1</sup>  
<sup>1</sup>National Research Institute of Police Science, Chiba, Japan; <sup>2</sup>Asahikawa Medical College, Asahikawa, Japan.
- 251 Accumulation of Mini-plasmin in the Cerebral Capillaries Causes Destruction of the Blood-brain Barrier (BBB) in Influenza-associated Encephalopathy (IAE) in Mice: Proposal for a Therapeutic Target Molecule of Brain Edema of IAE.  
**KIDO H**, YAMADA H, OKUMURA Y, YAO DF, CHEN Y, YANO M  
Institute for Enzyme Research, The University of Tokushima, Tokushima, Japan.

**Category: Adverse events, interactions and toxicity of antiinfectives**

**02:00 - 03:15 PM Room assignment will be printed in the final program**

- 365 A Mathematical Model for the Efficacy and Toxicity of Aminoglycosides.  
**C. NEEF**<sup>1</sup>, A .H. Koop<sup>2</sup>, S.A. van Gils<sup>2</sup>  
<sup>1</sup>Medisch Spectrum Twente, Enschede, The Netherlands; <sup>2</sup> University of Twente, Enschede, The Netherlands.
- 551 Effect of Rapamycin on Hepatocyte Function and Proliferation Induced by Growth Factors.  
**TOMIYA T**<sup>1</sup>, INOUE Y<sup>1</sup>, YANASE M<sup>1</sup>, ARAI M<sup>1</sup>, IKEDA H<sup>1</sup>, TEJIMA K<sup>1</sup>, NAGASHIMA K<sup>1</sup>, NISHIKAWA T<sup>1</sup>, WATANABE N<sup>1</sup>, OMATA M<sup>1</sup>, FUJIWARA K<sup>2</sup>  
<sup>1</sup>Department of Gastroenterology, University of Tokyo, Tokyo, Japan, <sup>2</sup>Third Department of Internal Medicine, Saitama Medical School, Saitama, Japan.
- 286 Fatal Adverse Drug Reactions (ADR): A Forensic Perspective on the Use of Anti-microbial and Anti-neoplastic Agents.  
**Lau G**  
Centre for Forensic Medicine, Health Sciences Authority, Singapore.
- 555 Cytochrome P450 Enzyme Activity Depression in Critically ill Patients: Cause of Drug Interactions involving Antimicrobial Agents.  
**PATIPARN TOOMTONG**<sup>1</sup>  
<sup>1</sup>Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- 048 HAART-ASSOCIATED METABOLIC SYNDROME AND CARDIOVASCULAR RISK.  
Giuseppe Barbaro, MD, **Giorgio Barbarini**<sup>1</sup>  
Department of Medical Pathophysiology, University of Rome "La Sapienza", Italy.  
<sup>1</sup>Department of Infectious and Tropical Disease, Policlinico S.Matteo, University of Pavia, Italy.

**Category: Clinical studies and use of antibiotics**

**02:15 - 03:30 PM Room assignment will be printed in the final program**

- 430 Consumer knowledge and demand for antibiotics; a Sri Lankan experience.  
**Premaratna R.**, Weerasinghe M., Vipulanayake T., Perera C., Balasooriya H. de Silva H.J.  
Department of Medicine, Faculty of Medicine, University of Kelaniya, Sri Lanka.
- 525 State of the Art: Lyme Disease and the Legacy of Paul Ehrlich.  
**STRICKER RB**<sup>1</sup>, LAUTIN A<sup>2</sup>, BURRASCANO JJ<sup>3</sup>  
<sup>1</sup>California Pacific Medical Center, San Francisco, CA, USA; <sup>2</sup>New York University School of Medicine, New York, NY, USA and <sup>3</sup>East End Medical Associates, East Hampton, NY, USA.
- 179 A Multispecies Biofilm Model Allows Prediction of Clinically Effective Concentrations of Antimicrobials in Oral Care Products.  
**B. Guggenheim**<sup>1</sup>, T. Boyd<sup>2</sup> and A. Gaffar<sup>2</sup>  
<sup>1</sup>University of Zurich, Institute for Oral Biology, Switzerland, <sup>2</sup>Colgate Palmolive Company, Piscataway, NJ, USA.
- 356 Role of Antiinfectives in the Treatment of Periodontitis.  
**NAGASAWA T**<sup>1</sup>, KOSHY G<sup>1</sup>, ISHIKAWA I<sup>1</sup>  
<sup>1</sup>Periodontology, Department of Hard Tissue Engineering, Graduate School, Tokyo Medical and Dental University.
- 097 Antibiotics in the Management of Acute Pharyngitis/Tonsillitis - Survey of Family Physicians in Northeastern Poland.  
**Chlabicz S**, Oltarzewska AM, Pytel-Krolczuk B  
Medical University Bilystok, Bialystok, Poland.

**Category: Role of cells and their staining by dyes**

**03:30 - 05:15 PM Room assignment will be printed in the final program**

- 359 Staining Bacterial Cells: From Ehrlich to the Present.  
**NANNINGA N**  
Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.
- 109 CELL STAINING WITH TRADITIONAL TURKISH MADDER ROOT.  
**CÜCER N**<sup>1</sup>, GÜLER N<sup>2</sup>, YAMAMQGLU N<sup>1</sup>, DEMIRTAS H<sup>1</sup>  
<sup>1</sup>Erciyes University, Medical Faculty, Medical Biology Department. Kayseri-TURKEY  
<sup>2</sup>Erciyes University, Veterinary Faculty, Pharmacology Department, Kayseri-TURKEY.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 159 Application of Quantitative Structure-Activity Relationships (QSAR) to Dye Affinity for Natural Fibre: a Challenge for the Domain.  
**FUNAR-TIMOFEI S**<sup>1</sup>, **KURUNCZI L**<sup>2</sup>, **SIMON Z**<sup>1</sup>  
<sup>1</sup>Coriolan Dragulescu' Institute of Chemistry, Timisoara, Romania; <sup>2</sup>Victor Babes' University of Medicine and Pharmacy, Timisoara, Romania.
- 015 Fluorescence dyes, a powerful tool for structural characterization of macromolecules and cells.  
**ALBANI JR**  
Laboratoire de Biophysique Moléculaire, Université des Sciences et Technologies de Lille, Villeneuve d'Ascq Cédex, France.
- 322 Intermolecular Interactions of Functional Dyes in the Solid State – Color Polymorphism in Fluorescent Pyazine Dyes –  
**MATSUMOTO S**<sup>1</sup>, **UCHIDA Y**<sup>1</sup>, **YANAGITA M**<sup>2</sup>  
<sup>1</sup>Yokohama National University, Yokohama, Japan; <sup>2</sup>Nippon Soda Co., Ltd., Chiba, Japan.
- 636 Bifunctional effect of 17 $\beta$ -estradiol on macrophage.  
**HONG MIN**, **ZHU QUAN**  
National Standard Lab of Pharmacology for Chinese Materia Medica, Nanjing, China.
- 580 The Use of Dyes in the Study of Microencapsulated Pheromone for Control of Oriental Fruit Moth.  
**Waldstein DW**<sup>1</sup>, **Gut L**<sup>2</sup>  
<sup>1</sup>Missouri State Fruit Experiment Station, SW Missouri State University, Missouri, USA  
<sup>2</sup>Michigan State University, Michigan USA.

**Category: Clinical studies and use of antibiotics**

**03:45 - 05:30 PM**

**Room assignment will be printed in the final program**

- 236 Antibiotic treatment of respiratory infections in cystic fibrosis (CF) – the Stockholm policy and perspective.  
**KARPATI F**, **Hjelte L**  
Stockholm CF Centre, Children's Hospital, Karolinska University Hospital, Huddinge, Sweden.
- 364 Hepatocyte growth factor is a rapid therapeutic indicator within the first day of treatment in pneumonia.  
**NAYERI F**<sup>1</sup>, **ABEDNAZARI H**, **MILLINGER E**<sup>1</sup>, **BRUDIN L**<sup>2</sup>  
University Hospital, Linköping<sup>1</sup> and County Hospital, Kalmar<sup>2</sup>, Sweden.
- 185 Role of different risk factors in the development of Bronchial asthma in Bangladesh: an age, sex and economic STATUS MATCHED PROSPECTIVE STUDY.  
**M Rashidul Hassan**<sup>1</sup>, **AKM Fazlur Rahman**<sup>2</sup>, **ARM Luthful Kabir**<sup>2</sup>, **M Ali Hossain**<sup>1</sup>, **Asif M Mahmud**<sup>1</sup>, **M Ruhul Amin**<sup>3</sup>, **Kazi S Bennoor**<sup>1</sup>, **M Mostafizur Rahman**<sup>1</sup> et al  
1.NIDCH, Dhaka. 2. ICMH, Dhaka. 3. BICH, Dhaka: Bangladesh.
- 060 Ehrlich's Theory Of Drug Action And Anti-tuberculous Gold Therapy.  
**TG BENEDEK**  
University of Pittsburgh, Pittsburgh, PA.
- 304 Antibiotics in nosocomial infection and Culture sensitivity - An experience over 25 years.  
**A.K.Mahapatra**  
Dept.of Neurosurgery, AIIMS, New Delhi-110029, India.
- 231 Impact of Extended Spectrum  $\beta$ -Lactamase Producers in the Management of Nosocomial Infections.  
**REBA** **KANUNGO\***, **ANANTHKRISHNAN**, **SHANMUGANATHAN**, **SANJAYBHATTACHARYA**, **S.KUMAR**, **RENU MATHEW\***, **SHASHIKALA\***, **&SRINIVASAN\***  
Department of Clinical Microbiology, Pondicherry Institute of Medical Sciences\*, JawharlallInstitute of Medical Education and Research Pondicherry India.
- 411 Beta-Lactam/Beta-Lactamase Inhibitor (BLBI) Antibiotics are a Rational Choice for Treatment of Serious Infection with Extended-Spectrum Beta-Lactamase (ESBL) producing Bacteria.  
**PETERSON, LR**  
Evanston Northwestern Healthcare Research Institute and Northwestern University, Evanston, IL, USA.

**Category: Antiinfectives - new and known synthetic compounds**

**03:45 - 05:30 PM Room assignment will be printed in the final program**

- 085 Anti-Microbial Efficacy of Hydroxyapatite-Chlorhexidine Coated External Fixation Pins.  
**CAMPBELL, AA**<sup>1</sup>, LI, XS<sup>1</sup>, NELSON, BJ<sup>2\*</sup>, BOTTONI, C<sup>3</sup>, DEJONG, ES<sup>4\*</sup>, BROOKS, DE<sup>4</sup>  
<sup>1</sup> Pacific Northwest National Laboratory, Richland WA  
<sup>2</sup> Dwight D. Eisenhower Army Medical Center, Ft Gordon, GA  
<sup>3</sup> Keller Army Community Hospital, West Point, NY  
<sup>4</sup> U.S. Army Institute of Surgical Research, Fort Sam Houston TX.
- 106 Antimicrobial Drug Discovery: Need For A More Integrated Approach !  
**COS P**<sup>1</sup>, VANDEN BERGHE D<sup>1</sup>, PIETERS L<sup>2</sup>, MAES L<sup>1</sup>  
<sup>1</sup> Laboratory for Microbiology, Parasitology and Hygiene, <sup>2</sup> Laboratory for Pharmacognosy and Phytochemistry, University of Antwerp, Belgium.
- 121 Ultrastructure of Tissue Barriers and Synthesis of Anti-Infectives Designed to Penetrate Them.  
MISTLBERGER K<sup>1</sup>, KREMSER C<sup>2</sup>, PASCHKUNOVA I<sup>3</sup>, SÖLDER E<sup>4</sup>, WIESER E<sup>1</sup>, GALANSKI M<sup>3</sup>, BARTSCH G<sup>5</sup>, KEPPLER B<sup>3</sup>, JASCHKE W<sup>2</sup>, HUGL B<sup>5</sup>, BUCHBERGER W<sup>7</sup>, TALASZ H<sup>8</sup> & **DEBBAGE P**<sup>1</sup>  
Depts. <sup>1</sup>Histol. Mol. Cell Biol., <sup>2</sup>Radiol., <sup>6</sup>Vasc. Surg., Clinical Chem. Biochem.; Clinics of <sup>4</sup>Ob. Gyn., <sup>5</sup>Urol., Medical Univ.; <sup>7</sup>Tirol Land Hosp. Innsbruck, Austria; <sup>3</sup>Inst. Inorg. Chem., Univ. Vienna, Austria.
- 389 A New Class of Potent Dual Acting Gyrase and Topoisomerase IV Inhibitors.  
**OLSON E**<sup>1</sup>, CHARIFSON P<sup>1</sup>, GRILLOT A-L<sup>1</sup>, GROSS C<sup>1</sup>, GROSSMAN T<sup>1</sup>, MANI N<sup>1</sup>, MOORE J<sup>1</sup>, NICOLAU D<sup>2</sup>, PARSONS J<sup>1</sup>, STAMOS D<sup>1</sup>, TESSIER P<sup>2</sup>,  
<sup>1</sup>Vertex Pharmaceuticals Inc., Cambridge, MA, U.S.A.; <sup>2</sup>Hartford Hospital, Hartford, CT, U.S.A.
- 569 A novel tetramethylpiperidine-substituted phenazine (B4125) with activity against multiple drug-resistant Gram-positive bacteria.  
**VAN RENSBURG CEJ**<sup>1</sup>, O'SULLIVAN JF<sup>2</sup>, HUYGENS F<sup>3</sup>.  
<sup>1</sup>University of Pretoria, Pretoria, South Africa, <sup>2</sup>University College Belfield, Dublin, Ireland, <sup>3</sup>Queensland University of Technology, Brisbane, Queensland.
- 047 Antifungal and Antimycobacterial Activity of New Imidazole and Triazole Derivatives. A Combined Experimental and Computational Approach.  
ZAMPIERI D<sup>1</sup>, MAMOLO MG<sup>1</sup>, VIO L<sup>1</sup>, FERRONE M<sup>2</sup>, PRICL S<sup>2</sup>, SCIALINO G<sup>3</sup>, and **BANFI E**<sup>3</sup>  
<sup>1</sup>Dept of Pharmaceutical Sciences; <sup>2</sup>Dept of Chemical, Environmental and Raw Materials Engineering; <sup>3</sup>Dept of Biomedical Sciences Microbiology Sect, University of Trieste, Trieste, Italy.
- 052 Predicting In-Vitro Permeability of Antimycotics Using Quantitative Structure-Activity Relationship (QSAR) Models.  
**BASAK SC**, MILLS D  
Natural Resources Research Institute, University of Minnesota Duluth, Duluth, MN, USA.

**Friday, September 10, 2004**

**Category: Mechanisms of pharmacological and biochemical action of antiinfectives**

**07:30 - 09:30 AM Room assignment will be printed in the final program**

- 491 The Role of Efflux Transporters in Drug Targeting.  
**SEELIG A**  
Biozentrum der Universität Basel, Basel, Schweiz.
- 334 Exploitation of Peptide and Amino Acid Permeases as Drug Transporters of Antifungals.  
**MILEWSKI M**  
Gdańsk University of Technology, Gdańsk, Poland.
- 113 The Mode of Action of Glutathione Peptides as Antiprotozoal Agents.  
**D'SILVA C**<sup>1</sup>, DAUNES S<sup>1</sup>, TOMAS A<sup>2</sup>, ALIBU V P<sup>3</sup>, CLAYTON C<sup>3</sup>  
<sup>1</sup>Department of Chemistry & Materials, Manchester Metropolitan University, John Dalton Building, Chester Street, Manchester, UK; <sup>2</sup> Department of Molecular Immunology, Instituto for Molecular and Cell Biology, Porto, Portugal; <sup>3</sup>ZMBH, Universität Heidelberg, Heidelberg, Germany.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 152 Kit for Instant Tc-99m Labeling of the Antimicrobial Peptide Ubiquicidin 29-41: A Specific Radiopharmaceutical for Bacterial Infection Imaging.  
**FERRO-FLORES G<sup>1</sup>**, ARTEAGA-MURPHY C<sup>2</sup>, PALOMARES-RODRIGUEZ P<sup>1</sup>, MELENDEZ-ALAFORT L<sup>3</sup>, PEDRAZA-LOPEZ M<sup>2</sup>  
<sup>1</sup>Instituto Nacional de Investigaciones Nucleares, Ocoyoacac, México; <sup>2</sup>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, DF, México; <sup>3</sup>Universidad Autónoma del Estado de México, México.
- 205 Infectomics: Creating Holistic Strategies for the Development of Antiinfectives against the Central Nervous System (CNS) Infection.  
HUANG SH<sup>1,2</sup>, ZENG FY<sup>2</sup>, JONG A<sup>1</sup>, WU CH<sup>1</sup>, HUANG SZ<sup>2</sup>  
<sup>1</sup>Childrens Hospital Los Angeles University of Southern California, Los Angeles, USA;  
<sup>2</sup>Shanghai Children's Hospital Shanghai Jiao Tong University, Shanghai, China.
- 343 Effect of Isoniazid (INH) on Viability, Cell Morphologies and Acid-fastness Properties of *Mycobacterium avium* NCTC 8559 During the Growth Cycle.  
**MOHAMAD S<sup>1</sup>**, IBRAHIM P<sup>2</sup>  
<sup>1</sup>School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia; <sup>2</sup> School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
- 482 Focus on Albendazole for Echinococcosis.  
**Hans G. SCHIPPER**  
Academic Medical Center, Amsterdam, The Netherlands.
- 261 Limitations of Virtual Screening: Experimental and Computer-Aided Search for Novel Inhibitors of *E. coli* Methionine Aminopeptidase.  
SCHIFFMANN R, **KLEIN CD**  
FR 8.2 Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken, Germany.

**Category: Clinical studies and use of antibiotics**

**07:30 - 09:30 AM**

**Room assignment will be printed in the final program**

- 149 First Line *Helicobacter pylori* Therapy – are Commonly Used Regimens the Most Appropriate Ones? A Review.  
**FARUP PG**  
Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, and Innlandet Hospital HF, Gjøvik, Norway.
- 316 Effect of Helicobacter Pylori (HP) Eradication in the Clinical Course of Recurrent Aphthous Stomatitis (RAS).  
**MARKOPOULOS AK**  
Aristotle University of Thessaloniki, Dept.of Oral Medicine and Maxillofacial Pathology, Thessaloniki, Greece.
- 326 EFFECTIVENESS OF ANTIINFECTIVES.  
**Ramona Mc Loughlin**, Colm O'Morain  
Adelaide & Meath Hospital, and Trinity College Dublin, Dublin.
- 010 Pattern of Antibiotic Therapy and Clinical Outcome in Acute Generalized Peritonitis in Semi-Urban and Rural Nigerian Community.  
**ADESUNKANMI A.R. K.**, BADMUS T.A., AGBAKWURU E.A.  
Department of Surgery, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
- 086 Reasons for Failure of Antibiotic Treatment in Patients with Pyogenic Liver Abscess (PLA).  
**CERWENKA H**  
Division of Visceral Surgery, Department of Surgery, Medical University of Graz, Austria.
- 498 A Prospective Study of Comparison of Efficacy of Two Combination Treatment Groups in Syndromic Treatment of Lower genital infections.  
**SHARMA JB<sup>1</sup>**, MITTAL S<sup>1</sup>, RAINA U<sup>2</sup>  
<sup>1</sup>All India Institute of Medical Sciences, New Delhi, India; <sup>2</sup>Lok Nayak Hospital, New Delhi, India.
- 574 Is Antiinfective Therapy the "Magic Bullet" in the Prevention of Preterm Delivery?  
**Vidaeff A**  
Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Texas Medical School at Houston, Houston, USA.
- 412 Antibiotic treatment of acute pyelonephritis: are we asking the right questions?  
MEZZA E<sup>1</sup>, BURDESE M<sup>1</sup>, COLLA L<sup>1</sup>, CONSIGLIO V<sup>1</sup>, TATTOLI F<sup>1</sup>, MADDALENA E<sup>1</sup>, SEGOLONI GP<sup>1</sup>, PICCOLI G<sup>1</sup>, **PICCOLI GB<sup>1</sup>**.  
Chair of Nephrology, Internal Medicine Department, University of Turin – Italy.

**Category: Pharmacokinetics and tissue penetration of antiinfectives**

**07:30 - 09:35 AM Room assignment will be printed in the final program**

- 112 Dose Adjustment of Ciprofloxacin in Renal Failure: Should we Reduce the Dose or Prolong the Administration Interval?  
**CZOCK D, KELLER F**  
University Hospital Ulm, Ulm, Germany.
- 124 Metabolism of Metronidazole in Early Stages of Chick Embryo - A Novel Model for Human Metabolism.  
**DEVARAKONDA R K, NARASIAH N AND VIDYASAGAR J**  
Cancer, Aging & Metabolism Research Division, Kakatiya University, University College of Pharmaceutical Sciences, WARNGAL, AP, India.
- 080 Tissue Penetration of Anti-infective Agents.  
**BROWN PD**  
Department of Basic Medical Sciences, Biochemistry section, University of the West Indies, Mona, Kingston, Jamaica.
- 209 Penetration of Anti-infectives into the Lung.  
**HUSSAIN, I and AMIN, MZ**  
Washington University St. Louis, MO USA.
- 330 Azithromycin (AZT) serum and mammary secretion concentrations after its intramammary (IMM) administration in healthy and mastitic cows.  
**MESTORINO N, TURIC E, PESOA J, ERRECALDE JO.**  
Department of Pharmacology. Facultad de Ciencias Veterinarias. Universidad Nacional de La Plata.
- 366 Antibiotic penetration of the blood-brain barrier pharmacokinetics in cerebrospinal fluid and neurotoxicity (Review).  
**Mirjana Nesin**  
Weill Medical College of Cornell University, New York City, N.Y., USA.  
Tissue concentrations - what does it matter from a clinical point of view?  
**Scaglione F.**  
University of Milan, Milan, Italy.
- 368 Extended Interval Dosing of Aminoglycosides in Neonates is Safe and Effective: Systematic Review and Meta-Analysis of Controlled Trials.  
**NESTAAS E<sup>1</sup>, BANGSTAD HJ<sup>2</sup>, SANDVIK L<sup>2</sup>, WATHNE KO<sup>2</sup>**  
<sup>1</sup>Hospital of Vestfold, Tønsberg, Norway, <sup>2</sup>Ullevål University Hospital, Oslo, Norway.

**Category: Antiinfectives - new and known synthetic compounds**

**07:30 - 08:45 AM Room assignment will be printed in the final program**

- 554 Search For A New Chemical Class Of Metallo-β-Lactamase Inhibitors: Reversing Bacterial Antibiotic Resistance.  
**TONEY JH, THOMAS, JD, MOLOUGHNEY, JG**  
Department of Chemistry and Biochemistry, Montclair State University, Upper Montclair, New Jersey, USA.
- 137 The Use of Antibiotics in Immobilized Form: A Controlled Drug Delivery System to Minimize the Risk of Drug Misuse/Misdose in Developing Countries.  
**EI Enshasy, H.A.**  
Mubarak City for Scientific Research, Alexandria, Egypt.
- 188 Design and Synthesis of Contact System Inhibitors for the Treatment of Infectious Diseases.  
RUSSELL, W<sup>1</sup>, FEX, T<sup>2</sup>, BJÖRCK, L<sup>1</sup> and **HERWALD, H<sup>1</sup>**  
<sup>1</sup>Section for Molecular Pathogenesis, Department of Cell and Molecular Biology, Lund University, Sweden and <sup>2</sup>Orbichem, Lund, Sweden.
- 210 New Anti-infective Agents Developed by Novel Chemo-combination Strategy.  
**HWU JR<sup>1</sup>, TSAY S-C<sup>2</sup>**  
<sup>1</sup>National Tsing Hua University, Hsinchu, Taiwan, R.O.C.; <sup>2</sup>Well-being Biochemical Corporation, Taipei, Taiwan, R.O.C.
- 363 Metal Complexes as Leishmanicidal Agents.  
**<sup>a</sup>NAVARRO M, <sup>a</sup>CISNEROS-FAJARDO E, <sup>b</sup>MARCHAN E.**  
<sup>a</sup>I.V.I.C. Centro de Química. Caracas. BIICA-U.D.O. Cumaná Venezuela.



**Category: Antineoplastic agents - new and known synthetic compounds**

**07:30 - 09:20 AM Room assignment will be printed in the final program**

- 244 Antitumor Active Metal Coordinated Compounds - New Concepts For Cancer Chemotherapy - A Review.  
**KEPPLER BK**  
Institute of Inorganic Chemistry, University of Vienna, Vienna, Austria.
- 030 Reactions of Potent Anti-Tumour Complex *trans*-[Ru<sup>III</sup>Cl<sub>4</sub>(ind)<sub>2</sub>]<sup>-</sup> with DNA-Relevant Nucleobase and Thioethers: an Insight into Biological Action.  
**ARION VB, EGGER A, REISNER E, CEBRIAN-LOSANTOS B, KEPPLER BK**  
Institute of Inorganic Chemistry of the University of Vienna, Austria.
- 183 Investigations into the Mechanism of Action of indazolium *trans*-[tetrachlorobis(1*H*-indazole)ruthenate(III)] – an Antineoplastic Ruthenium(III) Coordination Compound.  
**HARTINGER CG, SCHLUGA P, EGGER A, PONGRATZ M, ARION VA, JAKUPEC MA, GALANSKI M, KEPPLER BK**  
Institute of Inorganic Chemistry, University of Vienna, Vienna, Austria.
- 256 DNA Cleavage Activity of Diazonium Salts.  
**KIZIL M<sup>1</sup>, INCE YILMAZ E<sup>2</sup>, PİRİNÇÇİOĞLU N<sup>1</sup>, AYTEKİN Ç<sup>1</sup>, KIZIL G<sup>1</sup>**  
<sup>1</sup>Department of Chemistry, <sup>2</sup>Department of Biology, Faculty of Science, Dicle University, Diyarbakır, Turkey.
- 401 STI 571 Bullets Ionizing Radiation in HNSCC.  
**Francisco S. Pardo**, Weg Okenko, Joseph Aguilera, Jamie Milligan, Jean Wang  
Departments of Biology, Radiation Biology, Otolaryngology, and Radiation Oncology. University of California, San Diego, and the Moores UCSD Cancer Center, San Diego, CA USA.
- 101 Inhibition of cyclo-oxygenase 2 (COX-2) enzyme in breast cancer.  
CHOW LWC  
Hung Chao Hong Integrated Centre for Breast Diseases, University of Hong Kong Medical Centre, Hong Kong, China.
- 175 Are 2'-deoxyadenosine esters potential antileukemic drugs?  
**GRIEB P<sup>1</sup>, KRYCZKA T<sup>1</sup>, ANDRZEJEWSKA M<sup>2</sup>, STACHNIK K<sup>3</sup>, KAZIMIERCZUK Z<sup>1</sup>.**  
<sup>1</sup>Department of Experimental Pharmacology, Mossakowski MRC PAS, Warsaw, Poland; <sup>2</sup>Institute of Chemistry, Agricultural University, Warsaw, Poland; <sup>3</sup>Laboratory of Flow Cytometry, National Institute of Public Health, Warsaw, Poland.

**Category: Antivirals & Antifungals - clinical studies**

**07:30 - 09:45 AM Room assignment will be printed in the final program**

- 432 Combined Antiviral and Anti-inflammatory Therapy of Viral Pneumonia.  
**PRINCE GA<sup>1</sup>, BOUKHVALOVA M<sup>1</sup>, BLANCO J<sup>1</sup>**  
<sup>1</sup>Virion Systems, Inc., Rockville, Maryland, USA.
- 272 Antiviral maintenance therapy with interferon- $\alpha$  2b and ribavirin for recurrent hepatitis C after liver transplantation-----clinical and morphological benefits in the long-term follow-up.  
**A. Kornberg**, B. Küpper, A. Tannapfel, M. Hommann, U. Settmacher, J. Scheele.
- 042 Oral Valacyclovir Treatment in Herpetic Corneal Disease.  
**AVUNDUK AM, SÖZEN E, AKYOL N**  
Karadeniz Technical University, School of Medicine, Department of Ophthalmology. Trabzon-Turkey.
- 120 In-vivo Monitoring of Herpes Simplex Virus type 1 (HSV) Encephalitis with Positron Emission Tomography (PET).  
**BUURSMA AR<sup>1</sup>, KLEIN HC<sup>2</sup>, GARSEN J<sup>3</sup>, KEGLER D<sup>3</sup>, HOSPERS GAP<sup>1</sup>, VAALBURG W<sup>1</sup>, DE VRIES EFJ<sup>1</sup>**  
<sup>1</sup>Groningen University Hospital, Groningen, the Netherlands; <sup>2</sup>Centre for Mental Health Winschoten, Winschoten, the Netherlands; <sup>3</sup>National Institute for Public Health, Bilthoven, the Netherlands.
- 487 Use of HIV-1 p24 Antigen for Monitoring Continuous and Structured Antiretroviral Therapies and Implications for Therapeutic Vaccination.  
**SCHUPBACH J**  
Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland.
- 238 Prevention of Invasive *Candida* Infection in High-Risk Preterm Infants <1000 Grams Birth Weight.  
**D KAUFMAN**, R BOYLE, KC HAZEN, JT PATRIE, M ROBINSON AND LB GROSSMAN  
University of Virginia, Charlottesville, VA. USA.

- 472 SHOULD WE THINK FUNGUS IN POLYSYMPOMATIC PATIENTS ?  
A randomised, double-blind trial with nystatin versus placebo in general practice  
**Santelmann H**, Lærum E, Rønnevig J and Fagertun HE  
Institutt for Allmennmedisin og Samfunnsmedisin, Universitet i Oslo, Norge.
- 211 Antiinfectives Used for *Penicillium marneffe* Infection in HIV-Infected Patients: a Review.  
**IAMAROON A**<sup>1</sup>, PONGSIRIWET S<sup>1</sup>, THOSAPORN W<sup>1</sup>, VANITTANAKOM N<sup>2</sup>  
<sup>1</sup>Department of Odontology and Oral Pathology, Faculty of Dentistry; <sup>2</sup>Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- 347 Early Treatment of Candidiasis in Non-Neutropenic Critically Ill Patients.  
NOLLA-SALAS M<sup>1</sup>, **MONMANY J**<sup>2</sup>, GICH I<sup>3</sup>, IBÁÑEZ-NOLLA J<sup>4</sup>  
<sup>1</sup>Institut de Recerca\*. Emergency Department, Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Barcelona; <sup>2</sup>Internal Medicine Department\*; <sup>3</sup>Department of Epidemiology\*; <sup>4</sup>Emergency Department, Hospital General de Catalunya, Sant Cugat del Vallès, Barcelona.  
\*Hospital de Sant Pau, Universitat Autònoma de Barcelona. Barcelona. Spain.

**Category: Pharmacodynamics and experimental therapy of antiinfectives**

**08:00 - 09:30 AM Room assignment will be printed in the final program**

- 146 The Importance of Pharmacokinetic/Pharmacodynamic (PK/PD) Knowledge Discovery in the Development of Antiinfective Agents.  
**Ette EI**<sup>1</sup>, Chu H-M<sup>1</sup>, Ajayi FO<sup>2</sup>.  
<sup>1</sup>Vertex Pharmaceuticals, Cambridge, MA., U.S.A., <sup>2</sup>Proctor and Gamble, Pharmaceuticals Division, Cincinnati, OH., U.S.A.
- 212 FROM MAGIC BULLETS TO NANOTECHNOLOGY – WE HAVE COME A LONG WAY AND YET A LONG WAY TO GO FOR EFFECTIVE MANAGEMENT OF INFECTIOUS DISEASES.  
**Omer Iqbal**, MD, FACC., Jawed Fareed, Ph.D, FACB.  
Department of Pathology, Loyola University Medical Center, Maywood, IL, USA.
- 064 Correlation between antibiotic pharmacokinetics and antibiotic resistance.  
**E Bergogne-Berezin**  
Bichat University, Masson, Paris, France.
- 174 Intracellular Penetration and Activity of Levofloxacin in *Staphylococcus Aureus* Infected Human Monocytes.  
**GRELLET J**<sup>1</sup>, NGUYEN H<sup>1</sup>, SAUX MC<sup>1</sup>, QUENTIN<sup>2</sup>  
<sup>1</sup>Pharmacokinetics Laboratory, <sup>2</sup>Microbiology Laboratory, Bordeaux II University, Bordeaux, France.
- 235 Distribution of Metronidazole (MDZ) in Muscle Tissue of Healthy Volunteers (H) and Patients with Septic Shock (SS) and its Efficiency Against *Bacteroides fragilis* (Bf) in Vitro.  
**KARJAGIN J**, PÄHKLA R, KARKI T, STARKOPF J  
University of Tartu, Tartu, Estonia.
- 298 Non-antibiotic treatment of infections – some alternative strategies.  
**LJUNGH Å**  
Dept Medical Microbiology, Dermatology and Infection, Lund University, Lund, Sweden.

**Category: Pharmacokinetics and tissue penetration of antiinfectives**

**08:50 - 10:35 AM Room assignment will be printed in the final program**

- 621 Dosing Strategy for Antiinfectives in First-In-Human (FIH) Studies.  
**ZHU M**  
Clinical Drug Evaluation, Johnson & Johnson Pharmaceutical Research and Development LLC, New Jersey, USA.
- 644 Use of Modelling and Simulation in the development of Levofloxacin.  
**WEBER W**, RUEPPEL D  
Aventis Pharma Deutschland GmbH, Germany.
- 285 Influence of Sex on the Pharmacokinetics of Chosen Quinolone.  
**LAMPARCZYK H**, KONIECZNA L, CHMIELEWSKA A  
Medical University of Gdańsk, Gdańsk, Poland.
- 028 Amoxicillin (AMX) Clinical Pharmacokinetics (PK): past, present, and future.  
**ARANCIBIA A**  
Department of Pharmaceutical Sciences, University of Chile, Santiago, Chile.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 479 Pharmacokinetics and efficacy of old and new antifungal agents for the treatment of endogenous endophthalmitis.  
**SCHELENZ S**  
Norfolk & Norwich University Hospital, Norwich, United Kingdom.
- 575 Targeting of Amphotericin B using Lipid Nanospheres for the Treatment of Visceral Leishmaniasis.  
**VOBALABOINA V<sup>1</sup>**, VEERAREDDY PR<sup>1</sup>, AND ALI N<sup>2</sup>.  
1. University College of Pharmaceutical Sciences, Kakatiya University, Warangal, A.P-INDIA.  
2. Indian Institute of Chemical Biology, Jadavpur, Kolkata, INDIA.
- 199 Pharmacokinetics and effects of ribavirin by intravenous and intraventricular administration for the treatment of subacute sclerosing panencephalitis (SSPE).  
**Mitsuaki Hosoya<sup>1</sup>**, Hitoshi Suzuki<sup>1</sup>, Shuichi Mori<sup>2</sup>, Shiro Shigeta<sup>2</sup>  
<sup>1</sup>Department of Pediatrics and <sup>2</sup>Department of Microbiology, Fukushima Medical University School of Medicine.

**Category: Diagnostic tests in cancer / adverse events of cancer treatment & Adverse events of antineoplastic compounds**

**09:45 - 10:45 AM Room assignment will be printed in the final program**

- 247 Enhancing the "Magic Bullet": Bispecific antibody-polymer probe technology for gamma imaging of small vascular lesions in vivo.  
**KHAW BA<sup>1</sup>**, TEKABE Y<sup>1</sup>, DONAHAY T<sup>2</sup>, JOHNSON LL<sup>2</sup>.  
<sup>1</sup>Northeastern University, Boston, MA, USA, <sup>2</sup>Rhode Island Hospital, Providence, RI, USA.
- 384 Prognostic and Predictive Biomarkers in Breast Cancer.  
**O'DRISCOLL L<sup>1</sup>**, KENNEDY SM<sup>2</sup>, CROWN J<sup>1&2</sup>, CLYNES M<sup>1</sup>  
<sup>1</sup>National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; <sup>2</sup>St Vincent's University Hospital, Dublin 4, Ireland.
- 257 The Protective Effect of Melatonin on Cisplatin Ototoxicity.  
**Ahmet Kizilay<sup>1</sup>**, M. Tayyar Kalcioğlu<sup>2</sup>, Mustafa Iraz<sup>3</sup>, Ercument Olmez<sup>4</sup>, Mucahit Egri<sup>5</sup>, Orhan Ozturan<sup>6</sup>  
<sup>1,2,6</sup> Department of Otorhinolaryngology; <sup>3,4</sup>Department of Pharmacology; <sup>5</sup>Department of Public Health; Inonu University School of Medicine, Malatya, TURKEY.
- 328 Intestinal permeability (IP) in the assessment of intestinal toxicity of cytotoxic drugs.  
**MELICHAR B**, DVORÁK J, HYŠPLER R, ZADÁK Z  
Charles University Medical School, Hradec Králové, Czech Republic.

**Category: Antiinfectives - new and known non-synthetic compounds**

**09:45 - 11:00 AM Room assignment will be printed in the final program**

- 079 The Magic Bullet Nisin: Structural Insights and an Additional Mechanism of Action?  
**Breukink E<sup>1</sup>**, Hasper H<sup>1</sup>, Hsu, S-T D<sup>2</sup>  
<sup>1</sup>Department of Biochemistry of Membranes and <sup>2</sup>Department of NMR Spectroscopy Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, the Netherlands.
- 545 Nontoxic, antifungal plant defensins interact with fungal-specific sphingolipids.  
**THEVISSEN K<sup>1</sup>**, WARNECKE DE<sup>2</sup>, FRANCOIS IEJA<sup>1</sup>, AERTS A<sup>1</sup>, LEIPELT M<sup>2</sup>, HEINZ E<sup>2</sup>, CAMMUE BPA<sup>1</sup>  
<sup>1</sup>CMPG, K.U. Leuven, Kasteelpark Arenberg, Heverlee, Belgium; <sup>2</sup>Institut für Allgemeine Botanik, University of Hamburg, Hamburg, Germany.
- 526 Antimycobacterial and Antiplasmodial Activities of Curcuminoids and Analogues: Structure-activity Relationship Studies.  
CHANGTAM C<sup>1</sup>, THONGON N<sup>2</sup>, SAENBOONRUENG J<sup>2</sup>, **SUKSAMRARN A<sup>1</sup>**  
<sup>1</sup>Ramkhamhaeng University, Bangkok, Thailand; <sup>2</sup>National Center for Genetic Engineering and Biotechnology, Pathumthani, Thailand.
- 445 Eukaryotic antibiotic peptides as leishmanicidal agents. The target is not always the parasite.  
**RIVAS L<sup>1</sup>**, LUQUE-ORTEGA JR<sup>1</sup>; SAUGAR JM<sup>1</sup>, DEL SOL V<sup>2</sup>, MENÉNDEZ R<sup>3</sup>, VALENZUELA C<sup>4</sup>, FRESNO M<sup>2</sup>, MIRAS MT<sup>3</sup>, ANDREU D<sup>5</sup>.  
<sup>1</sup>Centro de Investigaciones Biológicas (CSIC) Madrid. <sup>2</sup>Centro de Biología Molecular (CSIC-UAM) Madrid (Spain), <sup>3</sup>Facultad de Veterinaria, UCM. Madrid, <sup>4</sup>Instituto de Farmacología (CSIC-UCM) Madrid (Spain). <sup>5</sup>Universitat Pompeu Fabra, Barcelona (Spain).
- 425 In vitro leishmanicidal activity of naphthylisoquinoline alkaloids.  
**Ponte-Sucre, A<sup>1,3</sup>**, Gronauer, T.<sup>2</sup>, Newman, S.<sup>2</sup>, Faber, J.<sup>2</sup>, Bringmann, G.<sup>2</sup>, Moll, H.<sup>1</sup>  
<sup>1</sup>Institut für Molekulare Infektionsbiologie, Universität Würzburg, Germany, <sup>2</sup>Institut für Organische Chemie, Universität Würzburg, Germany and <sup>3</sup>Laboratorio de Fisiología Molecular, IME, Universidad Central de Venezuela.

**Category: Mechanism of tumor development and growth**

**10:00 AM - 12:15 PM Room assignment will be printed in the final program**

- 339 TUMOR ANGIOGENESIS: KEY ROLE OF INTEGRINS.  
**Francesc Mitjans**  
Laboratorio de Bioinvestigación, Merck Farma y Química, S.A.
- 437 Cytoskeletal Actin Remodeling – A Potential Target for Cancer Therapy and Prevention.  
**JIANYU RAO<sup>1</sup>**  
<sup>1</sup>Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles.
- 624 Effect of circadian rhythm scrambling on toxicity and survival of tumor-bearing mice.  
**Alex Zvulunov,<sup>a,b</sup> Leah Peleg,<sup>b,c</sup> Rachel Carlebach,<sup>b</sup> Israel E. Ashkenazi.<sup>b</sup>**  
From <sup>a</sup>Division of Pediatric Dermatology, Schneider's Children Medical Center, Petah-Tiqva, the <sup>b</sup>Chronobiology Unit, Department of Human Genetics, Sackler School of Medicine, Tel Aviv University, Tel-Aviv, and <sup>c</sup>Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.
- 438 Malignant Transformation of Syrian hamster embryo cells by Malachite green is Associated with Abrogation of Cell Cycle Checkpoint Controls and Increased Expression of P38 MAP Kinase.  
**RAO KVK, BIPASHA BOSE**  
Chemical Carcinogenesis Group, Cancer Research Institute, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, India.
- 094 Application of Expression Genomics in Predictive and Personalized Medicine: Magic Gene Expression Profiles.  
**CHIN KV<sup>1,3</sup>, WONG YF<sup>2</sup>, LIN W<sup>3</sup>**  
<sup>1</sup>Susan Lehman Cullman Laboratory for Cancer Research and Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ; <sup>2</sup>Department of Obstetrics and Gynecology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong; <sup>3</sup>Imhoteq Co., Highland Park, NJ.
- 341 Tumor Hypoxia and Hypoxia-regulated Genes as Targets for Novel Anticancer Chemotherapy Strategies; Building on the Legacy of Paul Ehrlich and Otto Warburg.  
**AIRLEY RE<sup>1</sup>, MOBASHERI A<sup>2</sup>**  
<sup>1</sup>Tumor Metabolism and Therapeutics Research Group, School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, United Kingdom  
<sup>2</sup>Molecular Pathogenesis and Connective Tissue Research Groups, Department of Veterinary Preclinical Sciences, University of Liverpool, Liverpool, United Kingdom.
- 550  $\alpha$ -Tocopheryl succinate enhances the cytotoxic effect of immunological and chemotherapeutic agents.  
**Tomasetti M<sup>1</sup>, Alleva R<sup>2</sup>, Benassi MS<sup>3</sup>, Neuzil J<sup>4</sup>, Borghi B<sup>2</sup>, Procopio A<sup>1</sup>**  
<sup>1</sup>Department of Molecular Pathology and Innovative Therapies, Ancona, Italy; <sup>2</sup>Department of Anesthesiology, Bologna, Italy; <sup>3</sup>Laboratory of Oncology, Bologna, Italy; <sup>4</sup>School of Health Sciences, Southport, Queensland, Australia.
- 222 The mechanisms of all-trans retinoic acid and arsenic trioxide-induced disease remission of acute promyelocytic leukemia.  
**Yongkui Jing**  
Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA.
- 641 Mechanisms of epigenetic silencing in leukemias.  
**M. Buschbeck, A. Gutierrez, I. Joval, L. Morey, R. Villa and L. Di Croce**  
Center for Genomic Regulation, Barcelona, Spain.

**Category: In vitro action of antimalarials**

**10:45 AM - 12:30 PM Room assignment will be printed in the final program**

- 061 NOVEL NATURAL ANTIMALARIALS FROM PLANTS.  
**BENOIT-VICAL F**  
<sup>1</sup>Laboratoire de Chimie de Coordination du CNRS, <sup>2</sup>Laboratoire de Parasitologie-Mycologie, CHU Rangueil, Toulouse Cedex, France.
- 153 Novel Options of Anti-malarials Based on Sphingolipid Metabolism and Ceramide Cytotoxic Activity.  
**FLESCHER E<sup>1</sup>, PANKOVA-KHOLMYANSKY I<sup>2</sup>**  
<sup>1</sup>Tel Aviv University, Tel Aviv, Israel; <sup>2</sup>Weizmann Institute of Science, Rehovot, Israel.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 225 Critical Review of Methods for the Measurement of Antimalarial Drugs Activity.  
**Jouin H**<sup>1,2</sup>  
<sup>1</sup>Inserm U 547 Institut Pasteur, Lille, France  
<sup>2</sup>Unité d'Immunologie Moléculaire des Parasites, Institut Pasteur, Paris, France.
- 458 Malaria Vectors of *Anopheles* Hyrcanus Group in Korea and Other Asian Countries: Distribution, Habitats, Morphology and Molecular Characterization.  
**RUEDA, L. M.**<sup>1</sup>  
<sup>1</sup>Walter Reed Biosystematics Unit, WRAIR/Smithsonian Institution, Suitland, MD, USA.
- 502 Anti-adhesive peptides and antibodies as potential therapeutics for falciparum malaria.  
**SHERMAN IRWIN W.**, WINOGRAD, ENRIQUE  
University of California, Riverside, CA, USA.
- 567 Synergistic "Magic Bullet" Chemotherapy Effective Against Multiple Drug Resistant Malaria and Cancer *In Vivo*.  
**VAN DYKE K** (1) and YE Z (2)  
Biochemistry and Molecular Pharmacology, West Virginia University, Medical Center, Morgantown, WV, USA (1) and Academy of Traditional Chinese Medicine Beijing, China (2) and Cancer Biologics of America International Inc. (1).
- 591 Antimalarial Drug Resistance in *Plasmodium falciparum* – a Host of Challenges.  
**Wernsdorfer WH**<sup>1,2</sup>, Wernsdorfer G<sup>2</sup>  
<sup>1</sup>Division of Specific Prophylaxis and Tropical Medicine, Center for Physiology and Pathophysiology, Medical University of Vienna, Austria; <sup>2</sup>Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

**Category: Mechanisms of pharmacological importance**

**11:15 AM - 01:00 PM Room assignment will be printed in the final program**

- 592 Arsenic Trioxide Affects Signal Transducer and Activator of Transcription Proteins through Alteration of Protein Tyrosine Kinase Phosphorylation.  
**Wetzler M**  
Roswell Park Cancer Institute, Buffalo, NY, USA.
- 020 Interaction of Transported Drugs with the Lipid Bilayer and P-glycoprotein: Drug Transport is Mediated by a Solvation Exchange Mechanism.  
OMOTE H, **AL-SHAWI MK**  
University of Virginia Health System, Charlottesville, VA, USA.
- 053 Flow cytometry for the measurement of phagocyte functions.  
**BASSØE C-F**  
Medical Department, Haukeland University Hospital, Bergen, Norway.
- 155 S100A6 and CacyBP/SIP – Two Proteins Identified in Ehrlich Ascites Tumor Cells Potentially Involved in Degradation of  $\beta$ -Catenin.  
**FILIPEK A**  
Nencki Institute of Experimental Biology, Warsaw, Poland.
- 141 Ploidy cycles in tumours: A reproductive pathway?  
**ERENPREISA JE**<sup>1</sup>, CRAGG MS<sup>2</sup>, IVANOV A<sup>1,2</sup>, KALEJS M<sup>1</sup>, LIEBE B<sup>3</sup>, SCHERTHAN H<sup>3</sup>, ILLIDGE TM<sup>3</sup>  
<sup>1</sup>Latvian University Biomedical Research and Study Centre, Riga, Latvia; <sup>2</sup>Cancer Science Division, Southampton University, United Kingdom; <sup>3</sup>MPI for Molecular Genetics, Berlin, Germany.
- 195 Glutamine (GLN) – Magic Bullet in Treatment of Protein Wasting in Severe Illness.  
**HOLECEK M**  
Department of Physiology, Charles University School of Medicine, Hradec Kralove, Czech Republic.
- 177 Regulation of Renal Bicarbonate Transport: The Role of Sodium Bicarbonate Cotransporter – Carbonic Anhydrase Interaction.  
**GROSS E**  
Case Western Reserve University, Cleveland, OH, USA.

**Category: Targeted delivery of antineoplastic agents**

**11:15 AM - 12:30 PM Room assignment will be printed in the final program**

- 276 Prodrugs in Cancer Chemotherapy – An Overview of Active and Passive Targeting Strategies.  
**KRATZ F**  
Tumor Biology Center, Freiburg, Germany.
- 243 Lipidic carriers of siRNA: differences in the formulation, cellular uptake and delivery with plasmid DNA.  
Sebastien Spagnou, Andrew D. Miller and **Michael Keller**  
IC-VEC Ltd, London, UK.
- 151 Nanoparticles of Biodegradable Polymers for Cancer Chemotherapy.  
**FENG SS**  
Department of Chemical & Biomolecular Engineering and Department of Bioengineering, National University of Singapore.
- 180 Superparamagnetic Iron Oxide Nanoparticles as Magic Bullets for Cell Targeting.  
**GUPTA AK<sup>1</sup>**, **GUPTA M<sup>2</sup>**  
<sup>1</sup>Crusade Laboratories Limited, Southern General Hospital, Glasgow, U.K.; <sup>2</sup>Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, U.K.
- 018 Targeted Therapeutics in the Treatment of Cancer.  
**ALLEN, TM<sup>1</sup>**, **PONZONI, M<sup>2</sup>**, **PASTORINO, F<sup>2</sup>**, **SAPRA, P<sup>1</sup>**  
<sup>1</sup>Pharmacology, Univ. Alberta, Edmonton, Canada; <sup>2</sup>G. Gaslini Children's Hospital, Genoa, Italy.

**Category: Analytical techniques**

**12:30 - 01:45 PM Room assignment will be printed in the final program**

- The use of capillary electrophoresis to determine counterfeit antibiotics.  
**HOLZGRABE U**  
Institute of Pharmacy and Food Chemistry, University of Wuerzburg, Germany.
- 640 IMMUNOAFFINITY CAPILLARY ELECTROPHORESIS AS A TOOL FOR EARLY DIAGNOSIS OF SEPTIC SHOCK AND AS A POTENTIAL SCREENING TEST IN ITS PROGNOSIS.  
**Norberto A. Guzman**  
Bioanalytical Drug Metabolism, Johnson & Johnson Pharmaceutical Research and Development, Raritan, New Jersey, USA.
- 226 Use of Enzyme Linked Immunosorbent Assay (ELISA) for the Diagnosis of Clinically Suspected Referred Human Cystic and Alveolar Hydatidosis Cases in Nepal.  
**D.D. Joshi**, Mahendra Maharjan, Harish Joshi, P.B. Chand  
National Zoonoses & Food Hygiene Research Centre (NZFHRC), Chagal, Kathmandu, Nepal.
- 604 Detection of Leptospira Agglutination by using Flow-Cytometry Light Scatter Analysis: A New Approach for Serological Testing for Leptospirosis.  
**YITZHAKI S<sup>1</sup>**, **ZAHAVY E<sup>1</sup>**, **BARNEA A<sup>1</sup>**, **KEYSARY<sup>1</sup> A**  
Israel Institute for Biological Research Ness-Ziona, Israel.

**Category: Role of cells and their staining by dyes**

**12:40 - 02:35 PM Room assignment will be printed in the final program**

- 311 Location, Orientation and Dynamics of Fluorescent Dyes in Lipid Bilayer Membranes.  
**Krishna MMG<sup>1,2</sup>**, **Periasamy N<sup>1</sup>**  
<sup>1</sup>Tata Institute of Fundamental Research, Mumbai, India; <sup>2</sup>University of Pennsylvania School of Medicine, Philadelphia, USA.
- 296 Differential Cytoprotective Activity of Carboxyfullerene.  
**LIN H-S<sup>1</sup>**, **LIN T-S<sup>1</sup>**, **D'ROSARIO T<sup>1</sup>**, **LUH T-Y<sup>2</sup>**  
<sup>1</sup>Washington University, St. Louis, MO, USA, <sup>2</sup> National Taiwan University, Taipei, Taiwan.
- 559 The clinical and therapeutic relevance of cytokeratin immunostaining of metastatic adenocarcinomas.  
**Tot T**  
Department of Pathology and Clinical Cytology, Central Hospital, Falun, Sweden.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 348 The Role of the Eosinophil in Health and Disease.  
**<sup>1</sup>Moqbel R., <sup>1</sup>Odemuyiwa S.O., <sup>2</sup>Adamko D., <sup>3</sup>Ghahary A.  
Departments of Medicine<sup>1</sup>, Pediatrics<sup>2</sup> and Surgery<sup>3</sup>, University of Alberta, Edmonton, Alberta, CANADA.**
- 566 Mast cells and mastocytosis: From Paul Ehrlich to the current millennium.  
**Peter Valent**  
Department of Internal Medicine I  
Division of Hematology & Hemostaseology  
Medical University of Vienna, Austria.
- 600 Using microencapsulated iNOS-expressing cells as an 'artificial macrophage' to combat the infectious microbes and cancer.  
**WEIMING XU & LIZHI LIU**  
Wolfson Institute for Biomedical Research, University College London.
- 588 Mitochondria-Targeted Bolasomes as "Magic Bullets" on the Subcellular Level.  
**WEISSIG V**  
Northeastern University, Bouve College of Health Sciences, School of Pharmacy, Department of Pharmaceutical Sciences, Boston, MA, USA 340.

**Category: Antineoplastic agents - new and known synthetic compounds**

**12:45 - 02:30 PM**

**Room assignment will be printed in the final program**

- 415 More bullets against carcinomas: MUC1 epitopes, Flt3 ligand (Flt3L) and Pluronic block copolymers (PBC).  
**PISAREV VM<sup>1</sup>**, KINARSKY L<sup>1</sup>, CAFFREY T<sup>1</sup>, HANISCH F-G<sup>2</sup>, von MENS DORF-POUILLY S<sup>3</sup>, KABANOV A, Hollingsworth MA<sup>1</sup>, SHERMAN S<sup>1</sup>  
<sup>1</sup>Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA; <sup>2</sup>Institute of Biochemistry, Medical faculty, and Central Bioanalytics of the Center of Molecular Medicine, University of Cologne, Germany; Dept. of Obstetrics and Gynaecology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands.
- 186 Molecular Mechanism of Antitumour Effect of Diospyrin and Derivatives.  
**HAZRA B<sup>1</sup>**, DAS SARMA M<sup>1</sup>, KUMAR B<sup>1</sup>, DAS K<sup>1</sup>, PANDEY BN<sup>2</sup>, MISHRA KP<sup>2</sup>  
<sup>1</sup>Jadavpur University, Calcutta, India; <sup>2</sup>Bhabha Atomic Research Centre, Mumbai, India.
- 203 Drug Design of BPR0L075 as an Anti-Cancer Agent.  
**Hsing-Pang Hsieh<sup>1</sup>**; Jing-Ping Liou<sup>1</sup>; Chun-Wei Chang<sup>1</sup>; Ching-Chuan Kuo<sup>2</sup>; Yi-Ling Chang<sup>1</sup>; Fu-Ming Kuo<sup>1</sup>; Huan-Yi Tseng<sup>1</sup>; Wen-Yu Pan<sup>2</sup>; Ching-Ping Chen<sup>1</sup>; Yung-Ning Yang<sup>1</sup>; Chiung-Tong Chen<sup>1</sup>; Shioh-Ju Lee<sup>1</sup>; Jang-Yang Chang<sup>2</sup>  
<sup>1</sup>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taipei, Taiwan; <sup>2</sup>Divisions of Cancer Research, National Health Research Institutes, Taipei, Taiwan.
- 337 Oxazaphosphorinane Drugs. New Analogues and Metabolic Studies and New Therapeutic Approaches.  
**Konrad Misiura**  
Department of Bioorganic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Lodz, Poland.
- 614 Benefit of liposomes prepared from alkylphospholipids for the treatment of cancer.  
**ZEISIG R**, WALTHER W, FICHTNER, I.  
Max Delbrück Center for Molecular Medicine Berlin-Buch, Germany.
- 172 The X<sub>c</sub><sup>-</sup> Cystine/Glutamate Antiporter as an Anticancer Target - Evaluation of the Azocompound, Sulfasalazine (SASP).  
**GOUT PW**, WANG YZ  
BC Cancer Agency, Vancouver, Canada.
- 630 Amonafide: Past, Present and Future.  
**Braña MF1**  
Universidad San Pablo-CEU, Madrid, Spain.

**Category: Targeted delivery of antineoplastic agents**

**12:45 - 02:20 PM**

**Room assignment will be printed in the final program**

- Pharmacokinetics of high-molecular anticancer agents  
**Kloft C**  
Freie Universitaet Berlin, Institute of Pharmacy, Berlin, Germany.
- 284 Targeted drug delivery via reconstituted high density lipoproteins (rHDL).  
**LACKO AG**, NAIR, M. PARANJAPE S, MOOBERRY L, McCONATHY, WJ  
University of North Texas Health Science Center, Fort Worth, TX.

- 494 The Use of Modified Forms of the EGF Receptor Binding Fragment for Targeted Drug Delivery to Cancer Cells.  
**SEVERIN S.E.**, FELDMAN N.B., LUTSENKO S.V  
Research Institute of Medical Ecology, Moscow, Russia.
- 510 Targeted Delivery of Chemotherapy Drugs via a Prostate Specific Antibody Induces Apoptosis and Inhibits Cell Proliferation in Human Prostate Cancer Cells *in vitro* and Their Tumors in Nude Mice.  
**SINHA AA**<sup>1,2,4</sup>, WILSON MJ<sup>2,3,4</sup>, REDDY PK<sup>2</sup>, PRETLOW TG<sup>5</sup>  
<sup>1</sup>Depts. of Genetics, Cell Biol. & Develop., <sup>2</sup>VA Research Service, <sup>3</sup>Lab. Med. & Pathol., <sup>4</sup>Cancer Center, Univ. of Minnesota, Minneapolis, MN, and <sup>5</sup>Institute of Pathol., Case Western Reserve Univ., Cleveland, Ohio, USA.
- 132 Microdosimetry and Intratumoral Localization of Intravenously Administered <sup>131</sup>I Labelled Monoclonal Antibodies (mAb) are critical to successful Radioimmunotherapy (RIT) of lymphoma.  
**DU Y**, JOHNSON P, GLENNIE M, ILLIDGE T  
Cancer Sciences Division, University of Southampton, UK.
- 164 Identification of Target Genes in Oncology – The Genomic Approach.  
**GEBAUER G** (1+2), KRONES-HERZIG A (2), GLINSKY G (2), MCCLELLAND M(2)  
(1) Department of Cell and Molecular Biology, Sidney Kimmel Cancer Center, San Diego, CA, USA; (2) Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany.

**Category: Antimalarial compounds - clinical studies**

**01:30 - 03:00 PM**

**Room assignment will be printed in the final program**

- 108 Double-blind randomised controlled trial of malaria chemoprophylaxis in British soldiers, with extended follow-up.  
**Croft AM**, von Bertele MJ, Brutus EC  
Headquarters British Forces Germany Health Service, Mönchengladbach, Germany.
- 265 Relationship of Parasite Count Dropping Rate and Clinical Outcome in Severe Falciparum Malaria.  
**K H KOH**, P H CHEW.  
Sarawak General Hospital, Malaysia.
- 264 Hepatic dysfunction and hepatic encephalopathy in malaria.  
**KOCHAR DK**, AGARWAL P, KOCHAR SK, JAIN R, RAWAT N, POKHARNA RK, KACHHAWA S, SRIVASTAVA T  
S.P. Medical College, Bikaner – India.
- 637 Malaria Control Trials by Transmission Blocking with Primaquine.  
**ISHII A**  
Jichi Medical School, Tochigi, Japan.
- 227 Toxicity of Antimalarial Drugs: A review.  
**HUSSIEN O. ALKADI**  
Faculty of Medicine and Health Sciences, Sana'a University, Republic of Yemen.
- 434 Malaria Control – Prospects.  
**Raghunath, D.**  
Sir Dorabji Tata Centre for Research in Tropical Diseases Innovation Centre, Indian Institute of Science Campus, Bangalore.

**Category: Adverse events, interactions and toxicity of antiinfectives**

**02:30 - 04:30 PM**

**Room assignment will be printed in the final program**

- 293 DRUG INDUCED APLASTIC ANEMIA, REVIEW.  
**Micha Levy**  
Hebrew University Jerusalem, Israel.
- 065 Dose-Effects of Fluoroquinolones (FQs) on Intestinal Penetration, Hepatic Isoforms and DNA Damage in Rat.  
**BERTAZZONI MINELLI E**, BENINI A, DORIA D, FRANCESCHETTI P, and FRACASSO M E  
Dpt. Medicine and Public Health, Pharmacology Section, University of Verona, Verona, Italy.
- 001 Cefepime-induced Neurotoxicity: A Retrospective Review With a Proposed Mechanism.  
**ABANADES S**<sup>1</sup>, NOLLA J<sup>2</sup>, RODRÍGUEZ-CAMPELLO A<sup>3</sup>, ROSET PN<sup>1</sup>, FARRE M<sup>1</sup>  
<sup>1</sup>Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Barcelona, Spain  
<sup>2</sup>Hospital Universitari del Mar, Universitat Pompeu Fabra, Barcelona, Spain



World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- <sup>3</sup>Hospital Universitari del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.
- 246 Impaired Cognition as a Sensitive Index of Antibiotics' Behavioral Toxicity: A Review.  
**Khalifa AE**  
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
- 049 Interactions of Antiinfectives: A Review.  
**BARCIA E, NEGRO S**  
Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, Spain.
- 217 An Overview of Life-Threatening Interaction of Macrolides with Cardiovascular Drugs.  
**JAMALI F AND DAKHEL Y**  
Faculty of Pharmacy & pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
- 423 Interactions of Antiinfectives.  
**PONTALI E**  
Health services – Prison of Genoa; Genoa, Italy.
- 619 Enzyme Kinetics for Cytochrome P450 (CYP) Inhibition in Antiretroviral Therapy.  
**ZHI-YI ZHANG, NANCY Y WONG**  
Drug Safety and Disposition, Eisai Research Institute, Andover, MA, USA.

**Category: Antineoplastic agents - new and known non-synthetic compounds & Antineoplastic agents - clinical studies**

**02:45 - 05:00 PM**

**Room assignment will be printed in the final program**

- 340 Alpha-fetoprotein Growth Inhibitory Peptide as an Antineoplastic Therapeutic Agent: The Use of Peptides as Targeted Magic Bullets in *In Vitro* and *In Vivo* Models.  
MUEHLEMANN M, **MIZEJEWSKI GJ**  
Serometrix LLC, Syracuse, NY, USA.
- 489 MTC 170 – A novel endogenous magic bullet against cancer.  
**Schwamberger G**<sup>1</sup>, Freudenberg M<sup>2</sup>, Galanos C<sup>2</sup>  
<sup>1</sup> Dept. of Molecular Biology, University of Salzburg, Austria  
<sup>2</sup> Max-Planck-Institute for Immunobiology, Freiburg, Germany.
- 133 Overview of Violacein Biological Activities: Biochemical Aspects of Its Cytotoxicity and Strategies to Improve Its Effectiveness.  
**DURÁN N**<sup>1,2</sup>, JUSTO GZ<sup>3</sup>, BROMBERG N<sup>1</sup>, MELO PS<sup>3</sup>, HAUN M<sup>3</sup>, FERREIRA CV<sup>3</sup>, DE MELLO MP<sup>4</sup>, BINCOLETTO C<sup>2</sup>, DE SOUZA AO<sup>5</sup>, DE AZEVEDO MMM<sup>1</sup>, DE AZEVEDO MBM<sup>1</sup>, LEON LL<sup>6</sup>, DE CASTRO SL<sup>6</sup>  
<sup>1</sup>Instituto de Química, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil; <sup>2</sup>Universidade de Mogi das Cruzes, Mogi das Cruzes, SP, Brazil; <sup>3</sup>Instituto de Biologia, UNICAMP; <sup>4</sup>CBMEG, UNICAMP; <sup>5</sup>USP-RP, Ribeirão Preto, SP, Brazil; <sup>6</sup>FIOCRUZ, Rio de Janeiro, RJ, Brazil.
- 332 Effects of indole phytoalexins on growth of cancer cells.  
**MEZENECV R**<sup>1</sup>, PILATOVA M<sup>1</sup>, MOJZIS J<sup>1</sup>, KUTSCHY P<sup>2</sup>  
<sup>1</sup>Medical Faculty PJ Safarik University, Kosice, Slovakia; <sup>2</sup>Faculty of Science PJ Safarik University, Kosice, Slovakia.
- 470 Promotion of targeted anticancer apoptosis: a natural "magic bullet".  
**SALGANIK RI, ALBRIGHT CD, VAN DYKE TA**  
The University of North Carolina, Chapel Hill, NC, USA.
- 610 Anticarcinogenic Effects of *Panax ginseng* C.A. Meyer and Identification of Active Compounds, Including Enzymatically Producing Ginsenosides Rh<sub>2</sub>, Rg<sub>3</sub> and Rg<sub>5</sub> from Red Ginseng.  
**YUN T-K**  
Korea Institute for Cancer Chemoprevention, Seoul, Korea.
- 541 Stromal targeted therapy: will manipulation of the haemopoietic microenvironment improve outcomes in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML)?  
**S Tauro**  
University Hospital Birmingham NHS Trust, Edgbaston, Birmingham, UK.
- 513 Phase I/II study of adenovirus-interferon- $\gamma$  (TG1042) in primary cutaneous lymphomas (CL).  
**Slos P\***, Urosevic M, Bleuzen P\*, Bataille V\*, Burg G, Squiban P\*, Dummer R  
University Hospital Zurich, Switzerland. \*Transgene, Strasbourg, France.

- 570 The independent prognostic effect of co-morbidity in lymphoma patients: results from the population-based Eindhoven Cancer Registry.  
**D.J. VAN SPRONSEN**<sup>1</sup> (1), M.L.G. JANSSEN-HEIJNEN<sup>2</sup>, V.E.P.P. LEMMENS<sup>2</sup>, W.G. PETERS<sup>3</sup>, J.W.W. Coebergh<sup>2</sup>  
<sup>1</sup>Department of Medical Oncology, UMC St Radboud, Nijmegen, The Netherlands  
<sup>2</sup>Comprehensive Cancer Centre South, Eindhoven, The Netherlands  
<sup>3</sup>Department of Internal Medicine, Catharina Hospital Eindhoven, The Netherlands.

**Category: Clinical studies and use of antibiotics**

**02:45 - 05:15 PM Room assignment will be printed in the final program**

- 102 Azythromycin versus doxycycline treatment in early Lyme borreliosis: Clinical outcome and antibody response.  
**CHRISTOVA I**  
National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
- 345 Cerebral Blood Flow, Metabolism and Flux in Patients with Acute Bacterial Meningitis (REVIEW).  
**MØLLER K**  
Department of Infectious Diseases, University Hospital Rigshospitalet, Copenhagen, Denmark.
- 515 The Importance of Combating Plaque Biofilm for Oral and Systemic Health.  
**SOORY M**  
GKT Dental Institute, King's College London, UK.
- 549 Moxifloxacin as an Alternative Antimicrobial Prophylaxis of Bacteraemia Following Dental Procedures.  
**TOMÁS I<sup>1</sup>, LIMERES J<sup>1</sup>, ALVAREZ M<sup>2</sup>, LÓPEZ-MELÉNDEZ C<sup>2</sup>, MEDINA J<sup>3</sup>, DIZ P<sup>1</sup>.**  
1-Santiago de C. University, Spain; 2-Xeral-Cies Hospital, Vigo, Spain; 3-CHUS, Santiago de C., Spain.
- 522 An Overview of Skin Infections and Application of Non-invasive Methods for the Evaluation of the Skin Condition.  
**STAMATAS GN, KOLLIAS N**  
Johnson & Johnson, Skillman, New Jersey, USA.
- 524 The Potential Risk of Erythromycin as Empiric Therapy for Therapy Failure in Acute Respiratory Tract Infections.  
NYS S<sup>1</sup>, TJHIE JHT<sup>2</sup>, SPEE K<sup>1</sup>, BARTELDs AIM<sup>3</sup>, HEIJNEN MLA<sup>4</sup>, PEETERS MF<sup>5</sup>,  
**STOBBERINGH EE<sup>1</sup>**  
<sup>1</sup>University Hospital Maastricht, Maastricht; <sup>2</sup>PAMM Laboratory, Veldhoven; <sup>3</sup>Nederlands Instituut voor Onderzoek in de Gezondheid (NIVEL), Utrecht; <sup>4</sup>Centrum voor infectieziekten en Epidemiologie (RIVM), Bilthoven; and <sup>5</sup>Streeklaboratorium voor Volksgezondheid, Tilburg, The Netherlands.
- 419 Treatment of Streptococcus pneumoniae Bacteremia (SpB). Are Two Drugs Better than One?  
**Plouffe JF<sup>1</sup>, Martin D<sup>1</sup>**  
<sup>1</sup>University Hospital, Columbus, OH, USA.
- 204 Penicillin Remains the First Drug of Choice for the Treatment of Pneumococcal Pneumonia in Taiwan with High Rate of Penicillin Resistance in *Streptococcus pneumoniae*.  
**HSUEH PR,<sup>1</sup> HUANG WK,<sup>2</sup> TENG LJ,<sup>1</sup> SHYR JM,<sup>3</sup> LIU YC<sup>2</sup>**  
<sup>1</sup>National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei; <sup>2</sup>Kaoshiung Veterans General Hospital, Kaoshiung; <sup>3</sup>Taichung Veterans General Hospital, Taichung, Taiwan.
- 017 Determining the clinical utility of the urine pneumococcal antigen in the diagnosis and empiric management of community acquired pneumonia.  
**Zakari Y. Aliyu, DA Colvin, HM Saliu, DK Walshe, S Ondiek**  
St. Agnes Hospital, Baltimore Maryland.
- 135 Thyroid Tuberculosis: Diagnosis and Treatment about 8 cases.  
**EL MALKI H O<sup>1</sup>, BENJELLOUN H<sup>2</sup>, AMAHZOUNE M<sup>1</sup>, MOHSINE R<sup>1</sup>, CHEFCHAOUNI M C<sup>1</sup>, OULBACHA S<sup>1</sup>, IFRINE L<sup>1</sup>, BELKOUCHI A<sup>1</sup>, BALAFREJ S<sup>1</sup>.**  
<sup>1</sup>Clinique chirurgicale "A" Hôpital Ibn Sina, faculté de médecine et de pharmacie Rabat-Morocco  
<sup>2</sup>Cardiologie "A" Hôpital Ibn Sina, faculté de médecine et de pharmacie Rabat-Morocco.

**Category: Clinical studies and use of antibiotics**

**03:15 - 04:45 PM Room assignment will be printed in the final program**

- 633 The Future of Premature Infants During Paul Ehrlich's Time.  
**GOLOMBEK SG**<sup>1</sup>  
<sup>1</sup>The Regional Neonatal Center, Westchester Medical Center/New York Medical College, Valhalla, New York, USA.
- 586 Another Kind of Magic Bullet.  
**WARWICK WJ**  
Minnesota Cystic Fibrosis Center, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
- 240 Pediatric Febrile Neutropenia: 14 Years Experience.  
**R KEBUDI**<sup>1</sup>, **I AYAN**<sup>1</sup>, **Ö GÖRGÜN**<sup>1</sup>, **N GÜRLER**<sup>2</sup>  
Istanbul University, <sup>1</sup>Oncology Institute, Division of Pediatric Oncology, <sup>2</sup>Department of Microbiology, Istanbul, Turkey.
- 157 Is Prophylactic Administration of Antimicrobial Agents to Surgical Patients a Safe Procedure? The anesthesiologist's point of view.  
**FODALE V**, **PRATICO C**, **LUCANTO T**, **SANTAMARIA LB**.  
University Hospital, Messina, Italy.
- 279 Atypical Features of Leptospirosis – A Study at Pondicherry, India.  
**DUTTA TK**, **CHRISTOPHER MA**, **AHMED SM**, **KANUNGO R**, **DAS AK**  
Jawaharlal Institute of Postgraduate Medical Education & Research, Pondicherry, India.
- 013 Failure of a Short-Term Antibiotic Therapy for Human Brucellosis – What is Currently the State of the Art?  
**AL DAHOUK S**<sup>1</sup>, **NÖCKLER K**<sup>2</sup>, **TOMASO H**<sup>1</sup>, **HAGEN RM**<sup>1</sup>, **WITTIG M**<sup>1</sup>, **SCHOLZ HC**<sup>1</sup>, **NEUBAUER H**<sup>1</sup>  
<sup>1</sup>Bundeswehr Institute of Microbiology, Munich, Germany, <sup>2</sup>Federal Institute for Risk Assessment, Berlin, Germany.

**Saturday, September 11, 2004**

**Category: Microbiology & Resistance to antiinfectives**

**07:30 - 09:30 AM Room assignment will be printed in the final program**

- 270 Anaerobes and Production of  $\beta$ -Lactamases in the Upper Respiratory Tract in Early Childhood.  
**KÖNÖNEN E**  
National Public Health Institute (KTL), Helsinki, Finland.
- 605 Antibacterial Activities of Antibiotic Bonded/Impregnated Catheters.  
**YORGANCI K**<sup>1</sup>, **KREPEL C**<sup>2</sup>, **WEIGELT JA**<sup>3</sup>, **EDMISTON CE**<sup>2</sup>  
<sup>1</sup>Hacettepe University, Faculty of Medicine, Dept. of Surgery, Ankara, Turkey, Medical College of Wisconsin, <sup>2</sup>Surgical Research Lab. and <sup>3</sup>Dept. of Surgery, Milwaukee, Wisconsin, USA.
- 041 Antibiotics inhibiting the ribosome: structure and function.  
**AUERBACH T**<sup>1</sup>, **BARAM D**<sup>1</sup>, **ZARIVACH R**<sup>1</sup>, **SITTNER A**<sup>1</sup>, **BASHAN A**<sup>1,2</sup>, **PYETAN E**<sup>1,2</sup>, **SCHLUENZEN F**<sup>2</sup>, **HARMS J**<sup>2</sup>, **BERISIO R** AND **YONATH A**<sup>1,2</sup>  
<sup>1</sup>Weizmann Institute of Science, Rehovot, Israel, <sup>2</sup>Max-Planck Research Unit for Ribosomal Structure, Hamburg.
- 418 Phenotypic Resistance: The Next Battleground in Treatment Effectiveness.  
**PLOTKIN BJ**<sup>1</sup>, **KONAKLIEVA MI**<sup>2</sup>  
Midwestern University, Downers Grove Illinois, U.S.A.; American University, Washington, D.C., U.S.A.
- 070 Application of the Resistance Prevention Concentration (RPC) & Minimal Inhibitory Concentration (MIC) of Clinical Isolates of *Streptococcus pneumoniae* (SP) Against Macrolides.  
**BLONDEAU JM**<sup>1,2</sup>, **BORSOS S**<sup>1</sup>  
<sup>1</sup>Royal University Hospital, Saskatoon, SK, Canada, <sup>2</sup>University of Saskatchewan, Saskatoon, Canada.
- 206 Physiological costs of antibiotic resistance.  
**Hughes D**, **Macvanin M**, **Komp Lindgren P**, **Marcusson LL**, **Norström T**  
Department of Cell and Molecular Biology, Microbiology Programme, Box 596 BMC, Uppsala University, Uppsala, Sweden.

- 266 Efflux Mediated Antibiotic Resistance in Clinical Isolates of *Pseudomonas aeruginosa*.  
**T. Köhler**  
Dept. of Microbiology and Molecular Medicine, University of Geneva, Switzerland.
- 306 Antibacterial Photodynamic Inactivation of Multi-resistant *Staphylococci* Strains.  
**MAISCH T<sup>1</sup>**, BOSL C<sup>1</sup>, SZEIMIES R-M<sup>1</sup>, LOVE B<sup>2</sup>, ABELS C<sup>1</sup>  
<sup>1</sup>University Hospital of Regensburg, Germany, <sup>2</sup>Destiny Pharma, Brighton, UK.

**Category: Antiviral agents**

**07:30 - 10:00 AM**

**Room assignment will be printed in the final program**

- 414 Interferon; between magic bullet and panacea.  
**Toine Pieters**  
VU-Amsterdam Medical Centre, Department Metamedica, Amsterdam, The Netherlands.
- 466 Expression of Suppressor of Cytokine Signaling 3 (SOCS3) in Bone Marrow Cells from Chronic Myelogenous Leukemia (CML) Patients associated with Cytogenetic Response to Interferon-alpha (IFN- $\alpha$ ).  
**SAKAI I<sup>1</sup>**, TAKEUCHI K<sup>1</sup>, NARUMI H<sup>1</sup>, YASUKAWA M<sup>1</sup>, FUJITA S<sup>1</sup>  
<sup>1</sup>Ehime University School of Medicine, Sigenobu, Japan.
- 033 Elucidation of a Novel Molecular Mechanism by which Influenza Develops Resistance Against Amantadine, the M2 Channel Blocker.  
ASTRAHAN P<sup>1</sup>, KASS I<sup>1</sup>, COOPER MA<sup>2</sup>, **ARKIN IT<sup>1</sup>**  
<sup>1</sup>Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel; <sup>2</sup>Akubio Limited Cambridge, UK.
- 377 Antagonistic Combined Effects of Ribavirin and Some Picornavirus Replication Inhibitors.  
**Nikolaeva-Glomb, L** and Galabov, A S  
The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences.
- 540 Meclofenoxate (Centrophenoxine, Acephen, etc.) can inhibit the retrovirus budding on the plasma membrane of lymphoid line cells.  
**Tatariunas A.**  
Kaunas Medical University, Lithuania.
- 560 Antiretroviral compounds interfere with cytotoxic T lymphocytes functions.  
**TRABATTONI D<sup>1</sup>**, PICONI S<sup>1</sup>, BIASIN M<sup>1</sup>, SCHENAL M<sup>1</sup>, RUSCONI S<sup>4</sup>, CLERICI M<sup>1</sup>  
<sup>1</sup>Chair of Immunology, DISP LITA VIALBA, and <sup>2</sup>Infectious Diseases Clinic, University of Milano, Italy.
- 573 Biologic Properties of Structurally Modified  $\beta$ -Lactams Acting as Protease Inhibitors.  
**VEINBERG G**, VORONA M, SHESTAKOVA I, KANEPE I, LUKEVICS E  
Latvian Institute of Organic Synthesis, Riga, Latvia.
- 107 The stable cyclotide framework for the delivery of therapeutic peptides: anti-HIV activity of kalata B1.  
**CRAIK DJ<sup>1</sup>**, COLGRAVE ML<sup>1</sup>, DALY NL<sup>1</sup>, GUSTAFSON KR<sup>2</sup>  
<sup>1</sup>Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia. <sup>2</sup>Molecular Targets Development Program, National Cancer Institute, Frederick, USA.
- 421 Comparative Molecular Surface Analysis (CoMSA): Application for Diketoacid (DKA) Pharmacophore Mapping in HIV Integrase Inhibitors.  
**J. Polanski<sup>1</sup>**, H. Niedbala<sup>1</sup>, R. Musiol<sup>1</sup>, B. Podeszwa<sup>1</sup>, D. Tabak<sup>1</sup>, A. Palka, J.-F. Mouscadet<sup>2</sup>, R. Gieleciak<sup>1</sup>, A. Bak<sup>1</sup>, T. Magdziarz, J. Gasteiger<sup>3</sup>, M. Le Bret<sup>2</sup>  
<sup>1</sup>Department of Organic Chemistry, University of Silesia, Katowice, Poland, <sup>2</sup>CNRS UMR 8532, LBPA, Ecole Normale Supérieure de Cachan, Cachan, France, <sup>3</sup>Computer-Chemie-Centrum, Institute of Organic Chemistry, University of Erlangen-Nürnberg, Erlangen, Germany.
- 565 A primary macrophage model – a simple approach to study the effect of antiviral agents as well as host susceptibility to flavivirus West Nile.  
**PANTELIC L, UROSEVIC N**  
Microbiology, School of Biomedical and Chemical Sciences, The University of Western Australia, Nedlands/Perth, Australia.

**Category: Mechanisms of pharmacological importance**

**08:00 - 09:45 AM Room assignment will be printed in the final program**

- 239 Biochemical Characterization of the Doxorubicin Transporter from *Streptomyces peuceetius*.  
**KAUR P** and GANDLUR SM  
Department of Biology, Georgia State University, Atlanta, Georgia, USA.
- 221 The Antinociceptive response of *Buthus martensi* Karsch (BmK) AS, a Na channel Receptor Site 4 Modulator, and its possible underlying mechanism.  
JIN CHEN<sup>1</sup>, XING-HUA FENG<sup>1</sup>, JIAN SHI<sup>1</sup>, ZHI-YONG TAN<sup>2</sup>, **YONG-HUA JI**<sup>1CA</sup>  
<sup>1</sup>The Key Laboratory of Neurobiology, Institute of Physiology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai P.R. China; <sup>2</sup>Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut, USA.
- 275 Fluorescence Correlation Spectroscopy: a new tool for characterizing DNA plasmid condensation.  
**KRAL T**<sup>1,2</sup>, LANGNER M<sup>3,4</sup>, HOF M<sup>1</sup>  
<sup>1</sup>J. Heyrovský Institute, CAS and Center for Complex Molecular Systems and Biomolecules, Prague, Czech Republic, <sup>2</sup>Agricultural University, Wrocław, Poland, <sup>3</sup>Wrocław University of Technology, Wrocław, Poland, <sup>5</sup>Academic Centre for Biotechnology of Lipids Aggregates, Wrocław, Poland.
- 302 Fibroblastic Cells from Human Periapical Granulation Tissue (HFC) Preferentially Form Calcified Matrices in Rat Decalcified and Boiled Bone (DBB).  
**MAEDA H**<sup>1</sup>, WADA N<sup>1</sup>, FUJII S<sup>1</sup>, NODA R<sup>1</sup>, AKAMINE A<sup>1</sup>  
<sup>1</sup>Kyushu University, Fukuoka, Japan.
- 325 The c-kit mutation D816V induces differentiation and cluster formation in Ba/F3 cells and predicts the pathology and clinical course of indolent systemic mastocytosis.  
**Matthias Mayerhofer**, Peter Valent  
University of Vienna, Austria.
- 357 Relevance Of Surface Activity And Liquid Membrane Phenomena In Tissue Penetration And Drug Absorption.  
**Nagappa AN**<sup>1</sup>  
Pharmacy Group, Birla Institute of Technology and Science, Pilani, India.
- 373 Hypericin Derivative as a Magic Bullet for in vivo Targeting Hepatic and Cardiac Infarction.  
**NI Y**<sup>1</sup>, BORMANS G<sup>2</sup>, CHEN F<sup>1</sup>, FONGE H<sup>2</sup>, VERBRUGGEN A<sup>2</sup>, MARCHAL G<sup>1</sup>.  
Departments of Radiology<sup>1</sup> and Radiopharmaceutics<sup>2</sup>, University Hospital Gasthuisberg, K.U. Leuven, Belgium.

**Category: Clinical studies and use of antibiotics**

**08:15 - 09:30 AM Room assignment will be printed in the final program**

- 346 Prophylaxis of the Systemic Inflammatory Response Syndrome (SIRS) with N-acetylcysteine treatment: a Magic Bullet or a Fraud?  
**MOLNAR Z**  
University of Pécs, Pécs, Hungary.
- 589 A holistic approach to MRSA-eradication using intravenous linezolid/rifampicin, intratracheal vancomycin, nasal mupirocin, cutaneous and enoral chlorhexidin plus povidone-iodine in critical ill patients with MRSA-pneumonia.  
**Wenisch C**<sup>1</sup>, Krause R<sup>1</sup>  
<sup>1</sup>Infectious Diseases and Intensive Care, Medical University Graz, Austria.
- 315 The influence of local infusion of fusidic acid in the development of septic complications after lung resections.  
**MARKOGIANNAKIS A**<sup>1</sup>, SFYRIDIS P<sup>2</sup>, BALTAYIANNIS N<sup>2</sup>, TSAKRIS A<sup>1</sup>, HATZIMICHALIS A<sup>2</sup>  
<sup>1</sup>Faculty of Nursing, University of Athens, Greece; <sup>2</sup>Metaxa Cancer Hospital, Piraeus, Greece.
- 072 Infectious Complications in Hematopoietic Stem Cell Transplant Recipients: Experience at Pisa General Hospital.  
**M. Bonadio**, G. Morelli, S. Mori, R. Riccioni, E. Tagliaferri, M. Petrini  
Section of Infectious Diseases and Hematology Unit, University - Hospital, Pisa, Italy.
- 173 Six Years Experience of Using Meropenem & Vancomycin in First-line Empiric Antimicrobial Regimens in Paediatric Haematology & Oncology (PHO).  
**GRAY JW**  
Birmingham Children's Hospital (BCH), UK.

**Category: About mechanisms and Magic Bullets**

**09:45 - 12:00 PM Room assignment will be printed in the final program**

- 486 Magic Bullets and Lectins Reunited – Ehrlich's Contribution to Lectinology.  
**Schumacher U**<sup>1</sup>, Mewe M<sup>1</sup>, Thies A<sup>1</sup>, Schneppenheim R<sup>2</sup>, Pfüller U<sup>3</sup>, Tielker D<sup>4</sup>, Jäger KE<sup>4</sup>  
<sup>1</sup>Experimental Morphology, Hamburg, <sup>2</sup>Pediatric Oncology, Hamburg, <sup>3</sup>Phytochemistry, Witten-Herdecke, <sup>4</sup>Forschungszentrum Jülich.
- 004 Treatment of Glucosphingolipid Storage Disorders with Novel Inhibitors of Glucosylceramide Synthase.  
**ABE A**<sup>1</sup>, WILD S<sup>1</sup>, LEE L<sup>1</sup>, SHAYMAN JA<sup>1</sup>  
<sup>1</sup>University of Michigan, Ann Arbor, MI, USA.
- 022 How Does *Rhodococcus opacus* Adapt to Environmental Stresses?  
**ALVAREZ HM**, SILVA RA, ALVAREZ AF, BARRÍA M  
Departamento de Bioquímica, Facultad de Ciencias Naturales, Universidad Nacional de la Patagonia San Juan Bosco, Comodoro Rivadavia, Chubut, Argentina.
- 435 Ehrlich's "magic bullet" and current situation with infectious diseases.  
**SMITHYMAN AM**<sup>1</sup>, **RAJASEKARIAH GR**<sup>1</sup>  
<sup>1</sup>Cellabs Pty Ltd, Dale St, Brookvale, NSW, Australia.
- 046 FROM "BLUTGIFT" TO BIO - WEAPON: RICIN - 2004.  
**BALINT GA**  
Laboratory of Clinical Pharmacology, Dept. of Psychiatry; New Clinics; University of Szeged Medical School, SZEGED, HUNGARY.
- 310 SINGLE AGENT ONE DOSE THERAPY VERSUS MULTIPLE AGENT POLYTHERAPY FOR PROPHYLAXIS IN MINILAPAROTOMY HYSTERECTOMY: OUR EXPERIENCE.  
**MONIKA MALHOTRA**, JB SHARMA, R.ARORA, S BATRA  
Department of Obstetrics and Gynaecology, Maulana Azad Medical College, New Delhi, India.
- 455 Perilymph time-concentration profile of guinea pig cochlea after systemic and local application of caroverine.  
**CHEN Zhiqiang**<sup>a,b</sup>, **DUAN Maoli**<sup>b</sup>, **RUAN Runsheng**<sup>a,c</sup>, **ULFENDAHL Mats**<sup>b</sup>  
<sup>a</sup>Department of Otolaryngology, National University of Singapore, Lower Kent Ridge Road, Singapore  
<sup>b</sup>Department of Clinical Neuroscience and Center for Hearing and Communication Research, Karolinska Institutet, Stockholm, Sweden  
<sup>c</sup>Institute of Bioengineering and Nanotechnology, The Nanos, Singapore.
- 631 The Era of Targeted Therapies in Cancer.  
**Miguel H. Bronchud**  
Clinical Oncology, Hospital General of Granollers Barcelona- Spain.
- 646 Chaos, Cancer and The Cellular Operating System.  
**JONES AS**, TAKTAK A, FISHER A and HELLIWELL T  
The University of Liverpool, Faculty of Medicine.

**Category: Blood brain barrier**

**10:00 - 11:00 AM Room assignment will be printed in the final program**

- 008 Applications of a Blood-Brain Barrier Technology Platform to predict CNS penetration of drugs in various series of therapeutics families. I. Computational Model.  
**ADENOT M**<sup>1</sup>, PERRIERE N<sup>1,2</sup>, SCHERMANN JM<sup>2</sup>, LAHANA R<sup>1</sup>  
<sup>1</sup>Synt'em, Nîmes, France; <sup>2</sup>INSERM U26, Hôpital F.Widal, France
- 283 Neuroinflammation results in opening blood-brain barrier/BBB/ for peripheral peptides.  
**KWIATKOWSKA-PATZER B**, KLINOWIECKA A, KOSSON P, WALSKI M, FRONTCZAK-BANIEWICZ M, LIPKOWSKI AW  
Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
- 420 Pathological Opening of the Blood-Brain Barrier (BBB) to Horseradish Peroxidase (HP) and Amyloid Precursor Protein (APP) Following Ischemia-Reperfusion Brain Injury.  
**PLUTA R**<sup>1,2</sup>  
<sup>1</sup>Medical Research Centre, Warsaw; <sup>2</sup>Pedagogical University, Częstochowa, Poland.
- 076 MANIPULATING THE BLOOD BRAIN BARRIER FOR STEM CELL THERAPY IN STROKE  
**Cesar V Borlongan**<sup>1,2,3\*</sup>, Cyndy D Davis<sup>4</sup>, Paul R Sanberg<sup>4</sup>, <sup>1</sup>Dept Neurology, <sup>2</sup>Inst Molecular Medicine and Genetics, Medical College of Georgia; <sup>3</sup>Augusta VAMC, Augusta GA 30912; <sup>4</sup>Center of Excellence for Aging and Brain Repair, University of South Florida College of Medicine, Tampa FL.

**Category: Mechanisms of action of antineoplastic agents including resistance**

**10:10 - 11:40 AM Room assignment will be printed in the final program**

- 297 An ATP-Dependent Switch Controls the Transport Cycle of the Multidrug Resistance P-Glycoprotein.  
**LINTON KJ<sup>1</sup>**, ZOLNERCIKS JK<sup>1</sup>, WOODING C<sup>1</sup>, KERR ID<sup>2</sup> and HIGGINS CF<sup>1</sup>.  
<sup>1</sup>MRC Clinical Sciences Centre, London, UK. <sup>2</sup>University of Nottingham, Nottingham, UK.
- 099 Development Of a Novel Resistance Modifying Agent To Overcome Multidrug Resistance In Cancer.  
**S K CHOUDHURI**, P DUTTA, S MAJUMDER and A MOOKHERJEE  
Department of Environmental Carcinogenesis and Toxicology Chittaranjan National Cancer Institute, Calcutta, INDIA.
- 193 Multidrug Resistance Gene (*MDR1*) Polymorphism G1199A alters P-Glycoprotein Efflux Activity and Drug Resistance (new data).  
WOODAHL EL, YANG Z, BUI T, SHEN DD, **HO RJY**  
University of Washington, Seattle, WA, USA.
- 463 Possible Molecular and Cellular Action Mechanisms of Catechins Explaining the Beneficial Effects of catechins on the Development of Cancer Diseases.  
**AGAPIOS SACHINIDIS**  
Center of Physiology and Pathophysiology, Institute of Neurophysiology, Cologne, Germany.
- 625 Molecular mechanisms for the repair of DNA damage induced by anticancer topoisomerase inhibitors.  
**ADACHI N**, IIZUMI S, SO S, KOYAMA H  
Kihara Institute for Biological Research, Yokohama City University, Yokohama, Japan.
- 608 Magic bullet for breast cancer prevention: To prevent the formation of estrogen epoxide.  
**Yu FL**  
Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, USA.

**Category: Agents involving the immune system**

**11:15 AM - 01:00 PM Room assignment will be printed in the final program**

- 299 From the Magic Bullet to a Better Fort - Up Regulation of Host Immunity.  
**LORIA RM.**  
Virginia Commonwealth University, Medical Center, Dep of Microbiology, Immunology, Pathology and Emergency Medicine, Richmond Va. USA.
- 300 Magic Bullets for Cancer Drugs and Cancer Gene Therapy.  
**LUNDSTROM K**  
Regulon Inc./Cancer Therapeutic Sciences, Epalinges (Lausanne) Switzerland.
- 403 Magic bullets – magic ghosts: targeting of colon cancer cells and macrophages by bacterial ghosts loaded with doxorubicin.  
**PAUKNER S.<sup>1,2</sup>**, KOHL G.<sup>2</sup> AND LUBITZ W.<sup>1,2</sup>  
<sup>1</sup>Institute for Microbiology and Genetics, Vienna Biocenter, University of Vienna, Austria  
<sup>2</sup>BIRD-C GmbH & Co KEG, Vienna, Austria
- 433 Ehrlich ascites tumor as a tool in the development of compounds with immunomodulatory properties.  
**QUEIROZ MLS<sup>1</sup>**, VALADARES MC<sup>1</sup>, BINCOLETTTO C<sup>1,2</sup>  
<sup>1</sup>Departamento de Farmacologia/Hemocentro, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil; <sup>2</sup>Centro Interdisciplinar de Investigações Bioquímicas, Universidade de Mogi das Cruzes, Mogi das Cruzes, SP, Brazil.
- 578 Immunologically Specific Activation of Anticancer Prodrugs by Monoclonal Antibody  $\beta$ -Lactamase Conjugates.  
**VRUDHULA VM**, KERR DE, SIEMERS NO, SVENSSON HP, WALLACE PM, SENTER PD  
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, U.S.A.
- 603 Identification of a small molecule organic compound for prevention of complement-mediated immune hemolysis.  
**YAZDANBAKSHSH K<sup>1</sup>**, MQADMI M<sup>1</sup>, ZHENG X<sup>1</sup>, SONG J<sup>1</sup>, ABRAMOWITZ S<sup>1</sup>, GICLAS,P<sup>2</sup>  
<sup>1</sup>Complement Biology, New York Blood Center, New York, USA.  
<sup>2</sup>Complement Laboratory, Pediatrics Dept, National Jewish Medical and Research Center, Denver, USA.

World Conference on Magic Bullets  
Celebrating Paul Ehrlich's 150<sup>th</sup> Birthday  
Nürnberg, Germany, September 9-11, 2004

- 623 Knockdown of PU.1 by siRNA on CD34<sup>+</sup> Hematopoietic Stem Cells Derived from Mouse Embryonic Stem Cells Turns Cell Fate Determination to pro-B Cells.  
**ZOU GM**<sup>1,2</sup>, CHEN JJ<sup>1</sup>, WU W<sup>1</sup>, ROWLEY JD<sup>1</sup>  
<sup>1</sup>Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center; USA. <sup>2</sup>Current address: Herman B Well Center for Pediatrics Research, Indiana University School of Medicine.

**Category: Design of drug delivery & Vaccination**

**12:15 - 01:15 PM Room assignment will be printed in the final program**

- 118 Delivering the Magic Bullet: The Role of Transporters in Rational Drug Design.  
WALLACE LMJ, AJITH SN, AL-SALABI MI, BURCHMORE RJS, CANDLISH D, GOULD MK, JABEEN I, **DE KONING, H.P.**  
University of Glasgow, Glasgow, UK.
- 318 Receptor-Mediated Endocytosis: A Pathway for Drug Delivery and a Target for Drug Design.  
**V MARSHANSKY**  
Program in Membrane Biology, MGH, Department of Medicine, Harvard Medical School, Boston, MA, USA.
- 308 Interest of Fluorine-19 Nuclear Magnetic Resonance (<sup>19</sup>F NMR) to Detect, Identify and Quantify New Metabolites of Fluorinated Antifungal and Anticancer Drugs in Humans.  
**MALET-MARTINO M**, MARTINO R, GILARD V, DESMOULIN F  
Biomedical NMR Group, SPCMIB Laboratory, Paul Sabatier University, Toulouse, France.
- 126 Oral Vaccination Against Typhoid Fever.  
**Guido Dietrich**  
Berna Biotech Ltd, Berne, Switzerland.